Homeopathic complex

ABSTRACT

The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and/or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuriz calcareum or other similar profiled Calcarea or Sulphur salt or acid, Lachesis muta or other remedy with a similar profile, Mercurius Solubilis or similar mercury containing remedy and Silica or other silica containing compounds.

INCORPORATION BY REFERENCE

This application is a Continuation of U.S. application Ser. No.12/757,257 filed Apr. 9, 2010, which is a continuation-in-partapplication of International Patent Application Number PCT/EP2008/008602filed 10 Oct. 2008, which published as PCT Publication Number WO2009/047005 on 16 Apr. 2009, which claims benefit of Irish patentapplication Serial Number 2007/0737 filed 10 Oct. 2007.

The foregoing applications, and all documents cited therein or duringtheir prosecution (“appln cited documents”) and all documents cited orreferenced in the appln cited documents, and all documents cited orreferenced herein (“herein cited documents”), and all documents cited orreferenced in herein cited documents, together with any manufacturer'sinstructions, descriptions, product specifications, and product sheetsfor any products mentioned herein or in any document incorporated byreference herein, are hereby incorporated herein by reference, and maybe employed in the practice of the invention.

FIELD OF THE INVENTION

The present invention is directed to a homeopathic complex for use inthe treatment of various diseases or disorders, particularly for use asan anti-infective agent and/or in the regeneration of diseased ordamaged tissue.

BACKGROUND OF THE INVENTION

Homeopathy is a form of alternative medicine and traditional homeopathyhas been practiced for nearly two hundred years all over the world.Homeopathic medicine has its underpinnings in what is referred to as theLaw of Similars or the similia principle. The fundamental principle ofhomeopathy states that substances may be used to treat disorders whosemanifestations are similar to those which they themselves produce in ahealthy subject (Churchill Livingstone's International Dictionary ofHomeopathy Edited by Jeremy Swayne (2000) page 193, 1st Edition).

Homeopathic tinctures differ to herbal tinctures in their method ofproduction, base ingredients used and their dilution.

Homeopathic tinctures are derived from many materials, whereas herbaltinctures are derived from plant materials only. Homeopathic mothertinctures are made following monographs laid down in the HAB (GHP—GermanHomeopathic Pharmacopeia), EP European Pharmacopeia, French HomeopathicPharmacopeia BHP British Homeopathic Pharmacopeia HPUS HomeopathicPharmacopeia of the United States. While plants are the base ingredientsfor approximately 65% of homeopathic tinctures, the remainder are madefrom many mineral, animal or imponderable substances. Thus, theproduction of a homeopathic tincture involves the use of baseingredients from x-ray to diamond to Pulsatilla (the Wind flower).

A homeopathic mother tincture, comprising base ingredients such as forexample fresh plants, is generally prepared by extracting theingredients in a suitable solvent, followed by the steps of comminution,maceration and squeezing according to accepted homeopathicPharmacopoeia. Suitable solvents include alcohol, water, water-alcoholmixtures, glycerine or isotonic sodium chloride solutions. Othertechniques include tituration (grinding) with lactose to form a powdereddilution. On the contrary herbal tinctures are prepared in a differentmanner generally involving the use of a solvent to extract the baseingredient without the maceration or grinding steps.

In homeopathy, a base preparation or mother tincture of a homeopathicremedy is made by liquid extraction (via maceration) of a herbal,mineral, animal or imponderable substance by dissolving the herbal,mineral, animal or imponderable in a solvent. In use, the mothertincture or 1× potency (1×10⁻¹ dilution) may be used as is, for examplein diseases where the patient can benefit from the active principleswithin the tincture. This assumes that the base tincture is not of atoxic nature. Optionally, the mother tincture may be further diluted.Essentially, a series of dilutions are prepared from the basepreparation or mother tincture. This step is called potentization andinvolves a series of dilutions. Between each series the dilutedsubstance is succussed (shaken in a vigorous manner). The process ofdilution and succussion leads to a gradual loss of chemical toxicitywhile gradually increasing the homeopathic potency. The more diluteremedies being of greater potency.

Thus, homeopathic tinctures require a further dilution step in theproduction of the mother homeopathic tincture. This means that ahomeopathic mother tincture is a 1× or 1 in 10 dilution of the baseingredient. Additionally, it is important to note that it is notpossible to reconstitute a herbal mother tincture from a homeopathicmother tincture. Thus, what makes a tincture truly homeopathic is theadditional dilution process to where the final mother tincturerepresents a dilution of 1:10 of the base ingredient.

Thus, homeopathic tinctures differ to herbal remedies in that a furtherdilution is required in the production of homeopathic tinctures so thatthe base material is 10% of the final mother tincture. As expanded onabove a homeopathic mother tincture from fresh plants is prepared byextracting the ingredients in a suitable solvent, such as a alcohol,water-alcohol mixtures, water, glycerine or isotonic sodium chloridesolution are used as a vehicle (solvent) followed by the steps ofcomminution, maceration and squeezing. Other techniques includetituration (grinding) with lactose to form a powdered dilution. On theother hand, herbal remedies are less dilute than homeopathic remediesand are prepared in a different manner merely involving the use of asolvent to extract the ingredient.

Homeopathic preparations as defined above must follow the monograph aslaid down in the various homeopathic pharmacopoeias, for example theGerman Homeopathic Pharmacopeia (G.H.P. or H.A.B.), EuropeanPharmacopeia (E.P.), French Homeopathic Pharmacopeia, BritishHomeopathic Pharmacopeia (B.H.P.) or the Homeopathic Pharmacopeia of theUnited States (H.P.U.S.).

The dilution and sucussion level of homeopathic drugs are denoted as“x”, “X” or “d” for the decimal scale or centesimal “c”, “C” scale or LM(Q) as 1:50,000 dilutions. This is expanded in the table below.

Decimal Centesimal POTENCY DILUTION CONCENTRATION POTENCY DILUTIONCONCENTRATION 1x or D1 1:10 10⁻¹ 6c 1:10¹² 1 × 10⁻¹² 2x or D2 1:100 10⁻²7c 1:10¹⁴ 1 × 10⁻¹⁴ 3x or D3 1:1000 10⁻³ 11c 1:10²³ 1 × 10⁻²³ 4x or D41:10000 10⁻⁴ 12c 1:10²⁴ 1 × 10⁻²⁴ 5x or D5 1:100000 10⁻⁵ 30c 1:10⁶⁰ 6xor D6 1:1000000 10⁻⁶ 200c 1:10⁴⁰⁰ 30x or D30 1:10³⁰  10⁻³⁰ 1M 1:10²⁰⁰⁰10M 1:10²⁰⁰⁰⁰ LM1 (Q) 3c diluted 1:50,000

For example, for a “3×” preparation, the mother tincture is diluted withnine parts of the desired diluent, in either liquid or powder form. Theresultant mixture is then diluted a second time, in a ratio of one partmixture to ten parts solvent and the resulting mixture is diluted athird time in a ratio of one to ten. Therefore, the 3× or D3 potency isactually at 1×10⁻³ ( 1/1000) of the mother tincture. Similarly, a 6×potency dilution would be at 1×10⁻⁶ of the original solution. In the “Cscale” each dilution is done with ninety-nine parts diluent to theoriginal mixture. Therefore, a 3C potency dilution is at 1×10⁻⁶ potencyof the original mixture. Ideally, x potency dilution is usually carriedout with approximately 10 to 20 succussions, while C potency dilutionsare carried out with anywhere from 10 to 100 succussions and in somecases 1000 sucussions between dilutions. The more stages of dilution andsuccussion a homeopathic solution has undergone, the higher the potencyof that remedy.

These x and C scales are recognized by the main HomeopathicPharmacopoeia such as the German Homeopathic Pharmacopoeia (G.H.P.),French Homeopathic Pharmacopoeia British Homeopathic Pharmacopoeia, theHomeopathic Pharmacopeia of the United States (H.P.U.S.) and theEuropean Homeopathic Pharmacopeia.

When choosing the homeopathic remedy to administer, it is important tonote that the homeopathic approach to treatment hypothesizes that thecloser the matching of symptoms of the individual to be cured to thoseof the medicine being used, the greater the curing effect of thehomeopathic treatment. This process is facilitated by these symptomsbeing catalogued in the homeopathic Materia Medica and variousHomeopathic Repertories. The selection of the remedy is of primeimportance in a successful homeopathic treatment. Of secondaryimportance, is the selection of the correct therapeutic potency. Thepotency of the medicine must be matched to the state of the patient andthe state of the disease process. Thus, in a young healthy individualwith an acute disease process a high potency medicine would generally beappropriate, whereas in an elderly patient with a chronic disease a lowpotency or even a diluted LM potency may be more appropriate.

To demonstrate the effectiveness of a homeopathic drug, the drug istested by a “proving” in order to see how the drug will affect anotherwise healthy person. Hundreds of compounds have been tested in thismanner and these are catalogued in the various Homeopathic Repertoriesand Materia Medica. Homeopathic repertories generally provide listingsof the human anatomy (or in some clinical repertories clinicalconditions are listed) and list associated symptoms and treatments forthese symptoms. Materia Medicae list homeopathic drugs and identify themaladies and symptoms each drug treats. The material in the MateriaMedicae is derived from all the information about the homeopathic drugand includes data from homeopathic provings, toxicity, and clinical use.More over, where a repertory lists a symptom, it classifies possibletreating compounds as either first, second or third degree and in somecases fourth degree remedies for that symptom. Typically, a homeopathicpractitioner will prescribe homeopathic medicine that has the bestoverall recorded similarity to the overall disease picture in thepatient. This also involves taking into account how important eachsymptom is in that picture especially the strange rare and peculiarsymptom(s), mental, emotional, aetiological, general symptoms, localsymptoms and modalities. A homeopathic medicine with first degreeindications for a particular symptom picture is more likely to be usedthan a remedy with a similar second degree picture unless the seconddegree picture has a greater similarity to the overall patient picture.A homeopathic medicine with a third degree indication would be lesslikely to be used unless there was a greater similarity and particularlyif there was a strange rare and peculiar symptom present. Homeopathictinctures and their derivative potencies or dilutions can be used in thetreatment of a wide variety of diseases, conditions and or symptoms.

Classical homeopathy involves the administration of a homeopathicmedicine based on a single ingredient. The use of a homeopathic complexcomprising multiple different ingredients is contrary to conventionalclassical homeopathy teachings and in some pharmacopoeia this is notrecommended (“Hahnemann Revisited—A Textbook of Classical Homeopathy Forthe Professional” Luc DeSchepper, First Edition 2001, “Achieving andMaintaining the Similimum Strategic Case Management for SuccessfulHomeopathic Prescribing” LucDeSchepper, First Edition 2004, “The Organonof the Medical Art” by Samuel Hahnemann edited by Wenda BrewsterO'Reilly First Edition, 1996.)

The treatment of most conditions in humans or animals using conventionalmethodologies involves the administration of conventional drugtreatments. Such conventional treatments can have major side-effects tothe detriment of many internal organs. These side-effects, ranging frommild to severe, can prevent their application to many patients. Forexample, statins which are used in the treatment of high cholesterolhave many side effects ranging from mild to severe. These includegastrointestinal symptoms. Statins can also have severe side effect onthe liver and kidney. Rhabdomyolysis (the pathological breakdown ofskeletal muscle) may lead to acute renal failure when muscle breakdownproducts damage the kidney. Thus, with a condition like high cholesterolwhen it is being treated by statins, the patient must be continuallymonitored to assess whether unrelated systems are being adverselyaffected.

Many other therapies for a wide range of conditions also result in sideeffects ranging from mild to potentially lethal side effects. These sideeffects and other detrimental effects can also reduce patient complianceto the drug therapy. For example, many anti-arthritics andanti-inflammatories have side effects at the circulatory hepatic ornephrological level. Anti-anxiety drugs (anxiolytics) can have either asedative side effect or other often more hidden behavioural effects canoccur, such as dissociation or there may be a long term inability tocope without the drugs. It has been recorded that drugs used for thepurposes of sedation have in some cases resulted in the aggravation ofsymptoms such as aggression following their use. For example,acepromazine/acetylpromazine (ACP) is used as a sedative/tranquilizer byveterinarians. ACP is frequently used in combination with othersedatives and anaesthetics to provide smoother sedation ACP can causeside effects, such as effects on blood pressure. In some cases the lowerblood pressure remains long after the drug has been taken. Due to theseside-effects, it may not be possible to administer ACP to some animals.Anti-pruritic drugs, which reduce pruritus, or itching, can have sideeffects such as drowsiness and lowering blood pressure.

Therefore, it is desirable to provide a treatment which addresses theseissues and can mitigate at least some of the significant side-effectsand problems associated with conventional therapies.

Furthermore, another problem with current conventional methodologies isthat no therapy is 100% effective across a population no matter whatcondition is targeted. Any therapy which can improve effectivenessacross a wider range of subjects would be desirable.

There is a need for less expensive, safer and more user friendlytherapeutic agents for use in the treatment of a wide variety ofconditions. Hence, the present invention is directed to specifichomeopathic complexes which can treat a wide number of disorders withoutthe negative side effect and costs issues usually associated withconventional pharmaceuticals.

Citation or identification of any document in this application is not anadmission that such document is available as prior art to the presentinvention.

SUMMARY OF THE INVENTION

According to a general aspect of the present invention, there isprovided a homeopathic complex comprises a homeopathic tincture ordilutions thereof of a silica containing remedy, a mercury containingremedy, a snake or spider remedy, and a Calcarea or Sulphur salt oracid.

According to this general aspect of the invention, the homeopathiccomplex comprises a homeopathic tincture or dilutions thereof of Heparsulphuris calcareum [Hep] or other similar profiled Calcarea or Sulphursalt or acids, Lachesis muta [Lach] or other remedy with a similarprofile, Mercurius Solubilis [Merc] or Similar Mercury based remedy; andSilica [Sil] or other silica containing compounds.

According to a further general aspect of the present invention, there isprovided a homeopathic complex as defined herein for use as ananti-infective agent and/or in the regeneration of disease or damagedtissue.

According to a further general aspect of the present invention, there isprovided a method for the treatment or prophylaxis of infection and/orregeneration of disease or damaged tissue comprising administering to asubject in need thereof an effective amount of the homeopathic complexas defined herein.

Accordingly, it is an object of the invention to not encompass withinthe invention any previously known product, process of making theproduct, or method of using the product such that Applicants reserve theright and hereby disclose a disclaimer of any previously known product,process, or method. It is further noted that the invention does notintend to encompass within the scope of the invention any product,process, or making of the product or method of using the product, whichdoes not meet the written description and enablement requirements of theUSPTO (35 U.S.C. § 112, first paragraph) or the EPO (Article 83 of theEPC), such that Applicants reserve the right and hereby disclose adisclaimer of any previously described product, process of making theproduct, or method of using the product.

It is noted that in this disclosure and particularly in the claimsand/or paragraphs, terms such as “comprises”, “comprised”, “comprising”and the like can have the meaning attributed to it in U.S. Patent law;e.g., they can mean “includes”, “included”, “including”, and the like;and that terms such as “consisting essentially of” and “consistsessentially of” have the meaning ascribed to them in U.S. Patent law,e.g., they allow for elements not explicitly recited, but excludeelements that are found in the prior art or that affect a basic or novelcharacteristic of the invention.

These and other embodiments are disclosed or are obvious from andencompassed by, the following Detailed Description.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent of application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

The following detailed description, given by way of example, but notintended to limit the invention solely to the specific embodimentsdescribed, may best be understood in conjunction with the accompanyingdrawings, in which:

FIGS. 1A & 1B show the Feline of Example 2 pre-treatment and 24 hourslater;

FIGS. 2A & 2B show the “Sambo” Equine Gelding at Day 1/Day 11 of Example3A prior to treatment (FIG. 2A) and after treatment (FIG. 2B);

FIGS. 3A & 3B show the pig of Example 3b prior to treatment (FIG. 3A)and after treatment (FIG. 3B);

FIG. 4 show the Cavalier King Charles Female of Example 4 within 24hours start of treatment;

FIGS. 5A & 5B shows the Canine Collie of Example 5;

FIGS. 6A-6D show the Bichon Frise Male 6 years of Example 6. The stateof the wound is and the repairs due to the cream are shown in FIG. 6A to6D. FIG. 6B shows the change at day 12. FIG. 6C shows the change within30 days and FIG. 6D shows that within a year the scar was virtuallycompletely gone and almost the entire area had normal hair re-growth;

FIGS. 7A to 7D show the Cat of Example 8;

FIGS. 8A & 8B shows the cat of Example 9;

FIGS. 9A and 9B show the results of the non-nosode homeopathic treatmenton the IgG levels in a group of Lactating Holstein Cows for SubclinicalMastitis. Based on these results there is an effect even with out theinclusion of nosodes of Example 10;

FIGS. 10A to 10C show the dog of Example 11;

FIGS. 11A to 11B show the cat of Example 16;

FIGS. 12A and 12B show the dog of Example 17; and

FIGS. 13A to 13F show the cat of Example 20.

FIGS. 14A to 14G show the dog of Example 21.

FIGS. 15A-E depict the dog of Case Study 1 of Example 22. A. Woundcondition prior to general anaesthesia, 2 weeks post injury. B. 6 dayspost second anesthetic procedure and initiating therapy with HP VetCream. C. 6 days, and D. 21 days post second anaesthetic procedure andinitiating therapy with HP Vet Cream. E. Approximately one year later.

FIGS. 16A-C depicts the dog of Case Study 2 of Example 22. A. Clippedlesion on right pinna on day of presentation, B. Application of HP VetCream to the ear. C. 10 days post initial presentation with substantialhealing.

FIGS. 17A-C depict the dog of Case Study 3 of Example 22. A. Rightinguinal penetrating wound on the day of presentation, B. Followingtwice daily application of the homeopathic cream, the wound showedprogressive improvement after B., 2 weeks, and C. 4 weeks of treatmentinvolving only the application of HP Vet Cream.

FIGS. 18A-C depict the dog of Case Study 4 of Example 22. A. Wound onthe ventromedial surface of the stifle on the day of presentation, withevidence of infection. B. The wound at 2 weeks after initialpresentation following a course of amoxicillin/clavulanic acid and twicedaily application of HP Vet Cream. C. 4 weeks post initial presentation,with the homeopathic cream the only intervention during the previous 2weeks.

FIGS. 19A-D depict the dog of Case Study 5 of Example 22. A. Photographof the anesthetized dog's severe dorsal skin wound on presentation. B.24 hours post surgical repair and application of HomeoPet Vet Cream. C.21 days post surgery D. 1 year post surgery.

FIGS. 20A-B depict the animal of Case Study 142 in Example 23.

FIGS. 21A-B depict the animal of Case Study 143 in Example 23.

FIG. 22 depicts the animal of Case Study 144 in Example 23.

FIGS. 23A-C depict the animal of Case Study 145 in Example 23.

FIGS. 24A-C depict the animal of Case Study 146 in Example 23.

FIGS. 25A-C depict the animal of Case Study 147 in Example 23.

FIGS. 26A-C depict the animal of Case Study 148 in Example 23.

FIGS. 27A-B depict the animal of Case Study 149 in Example 23.

FIGS. 28A-B depict a patient of Example 24.

FIGS. 29A-C depict a patient of Example 24.

FIGS. 30A-E depict a patient of Example 24.

FIGS. 31A-B depict a patient of Example 25.

FIGS. 32A-B depict a patient of Example 25.

FIGS. 33A-B depict a patient of Example 25.

FIGS. 34A-B depict a patient of Example 25.

FIGS. 35A-B depict a patient of Example 25.

FIGS. 36A-B depict a patient of Example 25.

FIGS. 37A-B depict a patient of Example 25.

FIGS. 38A-B depict a patient of Example 25.

FIGS. 39A-B depict a patient of Example 25.

FIGS. 40A-B depict a patient of Example 25.

FIGS. 41A-G depict a patient of Example 26.

FIGS. 42A-C depict a patient of Example 26.

DETAILED DESCRIPTION

In the specification the term “by weight” refers to the weight of thefinal composition and “by volume” refers to the volume of the finalcomposition.

In this specification the term “homeopathic tincture and dilutionsthereof” includes a homeopathic mother tincture and/or its variousdilutions or potencies derived from the homeopathic mother tincture. Itwill also be understood that the homeopathic tincture comprises one ormore extracts derived from plant, mineral, animal and/or imponderablesubstances.

In the specification, it will be understood that the term“anti-infective” agent covers both “antimicrobial” or “antibacterial”effects and covers biocidal or biostatic activity against various typesof organisms including, but not limited to, bacteria, fungi, viruses,yeasts and/or moulds.

Finally, in the specification, it will be understood that thehomeopathic ingredients are referred to using different nomenclature orsynonyms. For example, Hepar sulphuris calcareum can also be referred toas [Hep] or Hepar sulphuris, they all refer to the same homeopathicingredient. Furthermore, for some ingredients, specific species namesare given in places and family names are given in other places. Forexample, Echinacea is generally referred to in the description whereasin the examples the preferred Echinacea plants are mentioned, such asEchinacea angustifolia [Echi] and Echinacea purpurea [Echi-p]. Thesecomments are applicable to most ingredients used in the homeopathiccomplexes of the invention. The different nomenclature andfamily/species for each ingredient is well known in the art and can befound in the homoeopathic literature. The following table highlights thedifferent names, long names and short names given to the samehomeopathic ingredient.

Name Of Remedy Abbreviation Alternative Nomeclature/Synonyms Heparsulphur hep. Hepar sulphuris calcareum; (Hep-s); The Calcarea sulphurataHahnemanni. Also impure Sulphide of Calcium Lachesis mutus Lach.Lachesis Muta; Bushmaster snake Lach. Lachesis muta. Bushmaster.Surukuku. Trigonocephalous lachesis Merc Sol Merc. Mercurius Solubilus;Mercurius Solublis Hahnemanni; Mercurius Merc-s., Merc., also MetallicMercury Quicksilver, Argentum vivum Silica terra Sil. Silica terraSilicea Terra Silicea Flint. Silex. Silicic anhydride. Silicon dioxide,Silicia Aconitum napellus Acon. Aconite., Monkshood. Wolfsbane. CommonAconite. N. O. Ranunculacee. Adrenalinum Adren. Adrenalinum. Extract ofadrenal glands. Sarcode Aesculus hippocastanum Aesc. Aesculus HorseChestnut. Aesculus hippocastanum. Hippocastanum vulgaris. N. O.Sapindaceae Alfalfa Alf Medicago sativa. California Clover. LucerneAntimonium tartaricum Ant-t Tartrate of Antimony and Potash. TartarEmetic. Antimonium tartaricum Apis mellifica. Apis. Apis-mel.,Honey-Bee. N. O. Insecta. Arnica montana Arn. Arnica., Leopard's Bane.Brusiewort. Fall Herb. N. O. Composite. Arsenicum album Ars. Ars Alb.,Arsen Alb., Arsencium Alb., Arsenic Trioxide. The white oxide ofmetallic Arsenic (Arsenicums) Arsenicum iodatum Ars-i. Ars Iod.,Arsenicum Iod., Iodide of Arsenic (Arsenicums and Iodatums) Astragalusmembranaceus Astra-m Astragalus membranaceus Astra-m. Astragalusmenziesii. N. O. Leguminose some confusion exists as to whether theseare fully the same from herb to homeopathy Aurum metallicum Aur Aur.Aurum metallicum. Metallic Gold. Baptisia tinctoria Bapt Baptisia. WildIndigo N. O. Leguminosae Baryta carbonica Bar-c. Baryta carb., Carbonateof Barium. Bar-c. with which are included symptoms of Baryta acetica.Belladonna Bell. Atropa belladonna. Deadly Nightshade. N. O. Solanaceae.Bellis perennis Bell-p. Daisy. N. O. Composite Berberis Vulgaris BerbBarberry. N. O. Berberidacae. Bryonia alba Bry. Bryonia. Bryonia dioica.Wild Hops. White Bryony. N. O. Cucurbitaceae Bufo rana Bufo Bufo., BufoSatytiensis. N. O. Bufonide, Batrachide. Toad Poison. Including thecommon variety, Bufo rana and the Brazilian toad, Bufo SatytiensisCactus grandiflorus cact Cact. Cactus grandiflorus. Cactus Selenicereus.Night-blooming Cereus. Cereus grandiflorus. N. O. Cactaceae Caladiumseguinum Calad. Calad. Caladium., American Arum. Arum seguinum. DumbCane. N. O. Araceae Calcarea carbonica Calc Calc Carb., Calcareacarbonica. Calcarea ostrearum. Conchae Praeparatae. Impure CalciumCarbonate. Calcarea fluorica Calc-f Calc Fluor., Calcarea fluorica.Calcium Fluoride. Fluorspar. Calcarea phosphorica Calc-p Calc Phos.,Calcium phosphate. Calcarea phos. Phosphate of Lime. Tricalcic PhosphateCalendula officinalis Calen. Calendula, Pot Marigold. N. O. Composite.Cantharis vesicatoria Canth. Cantharis., Spanish Fly. Lytta vesicator.N. O. Insecta, Coleoptera Carbo vegetabilis Carb-v Carbo vegetabilis.Vegetable Charcoal. Impure carbon Carduus marianus Card-m Carduus mar.St. Mary's Thistle. Silybum. N. O. Composite Chamomilla Cham. ChamomillaMatricaria German Chamomile N. O. Composite. Chelidonium majus. Chel.Chelidonium., Greater Celandine. N. O. Papaveracae. China officinalisChin. China., China Regia. Kina-Kina. Peruvian Bark. Cinchonacalisayaaut cinchona succirubra. N. O. Rubiacae Chionanthus virginicaChion. Fringe-tree bark. Chionanthus americana. N. O. Oleacee. Cocculusindicus. Cocc. Cocculus., Indian Cockle. N. O. Menispermacae. Coniummaculatum Con. Conium mac., Poison Hemlock. N. O. Umbelliferae. Crotalushorridus Crot-h. Crotalus-h., Crotalus horridus. The Rattlesnake (venom)Crotalidae Drosera rotundifolia Dros. Drosera. Round-leaved Sundew. N.O. Droseraceae. Echinacea angustifolia Echi. Purple Cone-flower.Echinacea angustifolia. Echinacea rudbeckia. N. O. Composite Echinaceapurpurea Echi-p. Black Sampson. N. O. Composite. Equisetum hyemaleEquis. Equisetum., Scouring-rush. Horse-tail herb. N. O. EquisetaceaeEuphrasia officinalis Euphr. Euphrasia. Eyebright. N. O. ScrofulariaceaeFerrum phosphoricum Ferr-p. Ferric Phosphate. Ferrum phosphoricum.Ferroso- ferric phosphate. White Phosphate of Iron, (Schusslers's).Galium aparine Gali. Galium ap. Goose grass. Cleavers. N. O. Galiacae,Gelsemium sempervirens Gels. Gelsemium., Yellow Jasmine. Gelsemiumsempervirens. Gelsemium lucidum. Yellow Jessamine. G. Nitidum. Bignoniasempervirens. N. O. Loganiacee. Graphites Graph. Graphites naturalis.Black Lead. Plumbago. Grindelia robusta. Grin. Grindelia squarrosa.Rosin-wood. N. O. Composite Gunpowder Gunp.Carbon-Sulphur-Kali-Nitricum. Black Gunpowder Hamamelis virginiana Ham.Hamamelis., Witch-hazel. Hamamelis macrophylla. Hamamelis dioica. N. O.Hamamelidacee. Histaminium muriatricum Hist. Imidazolethylamine.Histamine hydrochloricum Hydrastis canadensis Hydr. Hydrastis., GoldenSeal. The Orange-root. Yellow Puccoon. N. O. Ranunculacee. Hypericumperforatum Hyper. Hypericum., St. John's-wort. Hypericum perforatum. N.O. Hypericacee Iodium Iod Iodium purum. Iodine. An element. IpecacuanhaIP Ipecac., Ipec root. Cephaelis ipecacuanha. N. O. Rubiaceae Kaliumcarbonicum Kali-c Kali Carb., Kali carbonicum. Carbonate of potassium.Potassium Carbonate Kalium Iodatum Kali-i Kali Iod., Potassium iodide.Kali hydroiodicum. Solution. Lac caninum Lac-c Lac can., Dog's milk. Lacvaccinum defloratum Lac-d. Cow Skimmed Milk. Lac Vaccinum Lac-v LacBovinum., Cows Milk Lappa arctium Lappa. Arctium lappa. Burdock. LappaMajor. Lappa officinalis. Arcion, (Greek). Gobo. Great Clote Burre. N.O. Composite. Laurocerasus Laur. Cherry laurel. Cerasus Laurocerasus.Common Laurel. Prunus Laurocerasus. N. O. Rosacea. Lavendula vera Lav-vLavender Ledum palustre Led. Ledum., Marsh tea. Wild Rosemary. MarshCistus. Labrador Tea. N. O. Ericaceae Lobelia inflata Lob. Indiantobacco, Puke weed. N. O. Lobeliacee. Lycopodium clavatum LycLycopodium., Club moss. Muscus terrestris repens. Pes ursinus.Wolfs-claw. N. O. Lycopodiacee Mezereum Mez.. Daphne mezereum. Spurgeolive. Chameleons germanica. Mezereon. N. O. Thymelaceae MillefoliumMill. Millefolium Achillea. Yarrow. Achillea millefolium. N. O.Composite Natrium muriaticum Nat-m. Nat mur., Salt, Sodium chloride.Common Rock Salt Nitricum acidum Nit-ac. Nitric acid. Aqua Fortis.Solution. Nux vomica Nux-v. Nux., Poison nut. Strychnos Nux vomica. N.O. Loganiacae. Paeonia officinalis Paeon. Peony. N. O. Ranunculaceae.Phytolacca decandra Phyt. Phytolacca., Phytolacca decandra. Poke root.Poke weed. Virginian Poke. Pole-root. Red Ink Plant. Garget Weed,. N. O.Phytolaccaceae Phosphorus Phos. The Element Phosphorus - red amorphousPhosphorus Prednisolone Predn Prednisolone a synthetic corticosteroidPulsatilla pratensis Puls. Pulsatilla., Pulsatilla nigricans. Pulsatillapratensis. Anemone pratensis. Pasque-flower. Wind flower. N. O.Ranunculaceae Pyrogenium Pyrog. Pyrogen., Pyrogenium. Rotten meat pus.,Pyrexin. Sepsin. Ranunculus bulbosus Ran-b. Ranunculus. Buttercup.Bulbous Crowfoot. N. O. Ranunculacee Rhus toxicodendron Rhus-t. RhusTox., Poison oak. Rhus radicans. Rhus venenata Rhus-v. Rhus ven., Poisonelder. Poison Sumac. Swamp Sumac. N. O. Anacardiacae Rumex crispus Rumx.Rumex. Yellow dock. The Curled Dock. N. O. Polygonaceae Ruta GraveolansRuta. Ruta graveolens. Garden Rue. Bitterwort. N. O. Rutaceae Sabalserrulata Sabal Saw palmetto. Serenoa serrulata. N. O. Palmaceae Sepiaofficinalis Sep Sepia., Sepia succus. Cuttlefish Ink. Sepia officinalis.N. O. Cephalopoda. Sol Sol. Sol. Sunlight. Milk sugar is exposed toconcentrated sun's rays and stirred with a glass rod until saturated.Solidago virgaurea. Solid. Solidago., Goldenrod. N. O. Compositae,Stannum metallicum. Stann. Stannum Tin. Trituration of the pure metalStaphisagria Staph. Staphysagria. Delphinium staphysagria. Stavesacre.N. O. Ranunculaceae Stellaria media Stel. Chickweed. N. O.Caryophyllaceae Strophantus hispidus Stroph-h. Strophantus. Kombe seed.Onaye. Onage. Poison of Pahonias. N. O. Apocynaceae Sulphur Sulph.Sulphur Sublimatum. Brimstone. Sublimed Sulphur Symphytum officinaleSymph. Comfrey. Knitbone. Symphytum officinale. Healing Herb. N. O.Boraginaceae. Taraxacum officinale Tarax Taraxacum. Dandelion. Leontodumtaraxacum. N. O. Compositae Tarentula Cubensis Tarent-c. Tarentula Cub.,The Cuban tarentula. Tarentula cubensis. Mygale Cubensis. Aranea peluda.N. O. Araneideae Tarentula Hispanica Tarent. Spanish tarentula. Lycosatarentula. N. O. Araneideae. Thiosinaminum. Thiosin. Rhodallinum.Mustard seed oil. Allyl sulphocarbamide. Derived from Oil of Mustard-seed. Rhodallin Thuja occidentalis Thuj. Thuja., Arbor vitae. N. O.Coniferae Triticum repens Tritic. Triticum. Couch grass. AgropyrumRepens. Cutch- grass. Quitch grass. N. O. Gramineae Urtica urens Urt-u.Stinging nettle. Urtica dioica. The Common Nettle, has similar if notidentical properties. N. O. Urticaceae. Uva ursi Uva. Bearberry.Arctostaphylos. N. O. Ericaceae. Zincum metallicum Zinc Zincum Met. .Zinc. An Element. Zn. NOSODES Bacillinum Bac. A Tuberculosis Nosode.Bacillinum. A maceration made from a tubercular sputum. CorynebacteriumCoryne A Corynebacterium Nosode Tuberculinum Aviairae Tub- a. Aviantuberculosis - Chicken tuberculosis Tuberculinum Avis NosodesTuberculinum Bovinum Tub Bov Bovine Tuberculosis - Tuberculinum Bovinumof Kent sometimes same as below Tuberculinum Koch Tub. TuberculosisNosode. The Tuberculinum Bovinum of Kent. Tuberculinum of Koch. Liquidpotencies. Nosode is prepared either from tubercular abscess or from aglycerine extract of pure cultivation of human tubercular bacillus.Staph Aureus Nosode Staphycoc Staphylococcus bacteria. Staphylococcinum.Streptococcus Nosode Streptoc. Streptococcinum. Streptococcinumbacteria. Medorrhinum Med. Gonorrhea nosode.. Glinicum. Potencies of theVirus. Colibacillinum 1 Coli Coliform Nosode Colibacillinum 2 E. ColiEscherichia coli

According to a first aspect of the invention, there is provided ahomeopathic complex comprising a homeopathic tincture or dilutionsthereof of

Hepar sulphuris calcareum [Hep] or other similar profiled Calcarea orSulphur salt or acid;

Lachesis muta [Lach] or other remedy with a similar profile;

Mercurius Solubilis [Merc] or similar mercurius based remedy; and

Silica [Sil] or other silica containing compounds.

It will be understood that Hepar sulphuris calcareum [Hep], Lachesismuta [Lach], Mercurius Solubilis [Merc]; and Silica [Sil] may bereplaced or supplemented with the additional remedies as outlined below.The main characteristic of the additional remedies is that they havesimilar profiles to the remedy they replace or supplement.

Furthermore, it will also be understood that these remedies may bereplaced or supplemented with chemical equivalents or bioequivalents ofthe homeopathic remedies which essentially mimic the active moietywithin the homeopathic remedy and ideally results in an agent with asimilar profile to the homeopathic remedy. For example, venoms such assnake or spider remedies may be replaced by ammonium carbonate.Additionally and by way of non-limiting examples, the active agentwithin the Solanacea family (e.g. Belladonna, Strammonium, Hyoscyamus)are the alkaloids, particularly the tropane alkaloids, and the activeagent within the Loganiaceae family (e.g. Iganthia, Gelsemium, NuxVomica) is strychnine (Strychnos). Other chemical equivalents orbioequivalents of homeopathic ingredients are well known in the field.

According to a specific embodiment, Calc Sulph, Calc Sil or similarprofiled Calcarea or Sulphur or salts or acids thereof may be present inaddition to or instead of Hepar Sulph.

It will be understood that other similar snake or spider remedies with asimilar septic shock profile to Lachesis muta can be used. Such remediesinclude but are not limited to Crotalidae (crotalus Horridalus),Tarentula Cubensis and/or Pyrogen.

Mercurius Solublis can also be known as Hydrargyrum, Mercurius vivus,Argentum vivum, Mercurius Solublis Hahnemanni, Metallic Mercury orQuicksilver. It will also be understood that Mercurius Solubilis may bereplaced or complimented with many other mercury containing compounds.For example, Phytolacca decandra, also known as Vegetable Mercury, maybe used. Phytolacca decandra has a high Mercury content and similarinimicable relationship to Mercury as discussed below.

Silica [Sil] can be known under any of its synonyms, such as Silicaterra, Silicea terra, Flint, Silex, Silica anhydride, Quartz or Silicondioxide or may be replaced or complimented with many other silicacontaining compounds such as Silica Marina Sea Sand.

This homeopathic complex comprising a homeopathic tincture or dilutionsthereof of Hepar sulphuris calcareum or other similar profiled Calcareaor Sulphur salt or acid; Lachesis muta or other remedy with a similarprofile, such as a spider or snake remedy, Mercurius Solubilis or othermercurius containing remedy with a similar profile (such as Phytolacca(vegetable mercury)) and Silica or other silica containing compoundswith a similar profile other will be referred to as “Core A” within thespecification and examples.

Essentially, Core A provides a general anti-infective homeopathiccomposition for use in the treatment of general infections and/orsepsis. Core A is essential to all the homeopathic complexes of thepresent invention. Essentially, Core A functions to allow the abortion,resorption, discharge or absorption of pus formation which develops inassociation with an infection and/or sepsis/septic infection.

Core A also provides for the re-growth and repair of damaged tissues.

This specific combination of the four homeopathic ingredients in Core Aprovides general anti-infective activity and is a combination whichwould not be recommended in most conventional homeopathic literature dueto incompatibility of two of the ingredients. However, contrary toconventional teachings, Applicants have found this specific combinationis well tolerated and provides good general anti-infective activity.

Specifically, according to general homeopathic teachings MercuriusSolubilis and Silica are incompatible (Remedy Relationships by ThomasBlasig & Peter Vint 1^(st) Ed 2001 Published Hahnemann Institut) SilicaTerra (Sil) and Mercurius Solubilis (Merc and Sil) should never be givenimmediately before or after each other. They are in homeopathic terms,“inimical” or incompatible (Nature's Materia Medica, January 2007 (3rdEdition) (Lotus Materia Medica (1^(st) & 2^(rd) Edition) Robin Murphy)and Concordant Materia Medica (First edition 1994) Frans Vermeulen)).Based on classical homeopathic teachings, these ingredients interferewith the action of the other. However, Applicants have surprisinglyfound that the homeopathic of the present invention uses both thesehomeopathic ingredients together without any detrimental effect.

Thus, unexpectedly and contrary to conventional homeopathic teachings,Core A advantageously provides for the dual functionality in termsanti-infective activity and re-growth and repair of damaged tissues ofthe homeopathic complex of the present invention. Thus, using thisknowledge it was possible to combine mercury and silica in a way thatwas beneficial to the patient in need thereof. This has been used toadvantage in a broad way in Core A.

Preferably, the homeopathic complex is provided in a potency range frommother tincture to approximately 100M (MM), preferably from mothertincture to 50M (CM) and including LM potencies.

Generally, a “low potency” according to the invention is in the “X”range and is ideally used for topical administration and the treatmentof chronic conditions. It may also be used internally to treat the sameinfection state.

For such topical use “X” or decimal potencies are most appropriate dueto their suitability for repeated use on a local area over a period oftime, without inducing a homeopathic aggravation. When this homeopathiccomplex is made in such low potencies up to 18×/9c, preferably frommother tincture to approximately 9c, more preferably from mothertincture to approximately 18× (18× and 9c are roughly equivalent interms of dilution) it is ideal for topical use, for example as a topicalanti-infective cream, gel or liquid healing composition. This comment isapplicable to all cores (i.e. Core A and the following Cores) and allcombinations of cores. There are some exceptions to this rule forexample. It will be understood that some homeopathic ingredients may beadministered as a mother tincture, however, due to Regulatoryconstraints in some countries, some homeopathic ingredients may not beadministered as a mother tincture and must be diluted to 2×, preferably6× or 8× or higher for administration. A few non-limiting examplesinclude Aesculus hippocastanum, Arsenicum Album, Cantharis, Gelsemium,Mezereum, Nux Vomica, Phosphorus Staphysagria, Nosodes from theadditional Cores C to D would not generally be recommended for used aMother Tincture because of Regulatory constraints in terms of safetybelow certain potencies. This is explained in more detail in the variouspharmacopeia, for example, the German or American HomeopathicPharmacopeia.

When this formulation is made in “high potencies” according to theinvention, in the C potency range, preferably 30c plus, more preferably200c plus, it is ideal for internal use, for example as a liquid fororal or internal administration. Thus, at these potencies, thehomeopathic complex works as an internal anti-infective healingcomposition. Again, this comment is applicable to all cores (i.e. Core Aand the following Cores) and all combinations of cores. In somesituations, there are exceptions to this rule for example, Arsenicumlod, Hydrastis, Laurocreasus and Gun Powder (which may be used inaddition to Core A) can also be used in the low potency range even whenformulated for internal administration, as they and other homeopathicingredients demonstrate significant effects in low potency.

Preferably, “high potency” according to the invention is from about 30cto about 1M.

“Very high potency” according to the invention is generally from about1M to 10M, and includes LM potencies.

In the “high” to “very high potency” (C or M potency dilution), thehomeopathic works as an acute anti-infective healing composition insituations needed a fast-acting response, for example an anti-infectivehealing first aid remedy. Thus, when used internally, it will beunderstood that a high potency in the C range to 1M is generally usedfor the treatment of acute conditions. The high to very high potencieswork best in acute conditions particularly as a complex for first aidtreatment from such minor injuries as cuts and grazes to such majorevents as strokes or traumatic injuries. However, it will also beunderstood that the general anti-infective composition or mastitistreatment composition of the invention can also be used in highpotencies for the internal treatment of infections and/or mastitis.

When the homeopathic composition of the invention is given internally atlow potencies, generally speaking Core A causes an abscess to ruptureand at high potencies, generally speaking Core A causes an abscess to beabsorbed. Applicants have also found that at potencies fromapproximately 9c to around 30c, so called “medium” potencies (betweenthe low and high potencies), that the homeopathic complex can cause bothpromote or prevent absorption of the abscess or promote or preventrupturing.

Thus, the potency of the homeopathic ingredients will generallydetermine whether it can be applied topically or internally to achievethe best results. This unexpected “biphasic” effect of the compositionat different potencies, was observed by the inventors in animals,particularly canines, when the homeopathic composition was administered.At different potencies the homeopathic ingredients work in differentways and should be administered in different ways.

The homeopathic complex according to the present invention can be usedas an anti-infective agent in the prophylaxis or treatment of microbialinfections.

When used as an anti-infective agent, the homeopathic complex can treatmost general microbial infections or sepsis. Advantageously, it has beenfound that the homeopathic complex according to the present inventioncan be used in the treatment of Methicillin-resistant Staphylococcusaureus (MRSA) or other associated conditions, including other antibioticresistant bacteria or pathogens. In this manner, the homeopathic complexof the invention can provide the effect of a conventional antibioticwithout the many side effects associated with such conventionaltreatments.

Some non-limiting examples of microbial infections include externalmicrobial infections of the skin, eyes (including conjunctivitis),nails, hoof, ears (including otitis) Some non-limiting examples ofmicrobial infections include internal microbial infections such asmastitis, pneumonia, metritis, joint infections; abscesses acute,chronic, resorptive stage; infected, inflamed or swollen glands.

Additionally, it has been found that the homeopathic complex accordingto the invention also promotes the regeneration of diseased and/ordamaged tissue which includes the re-growth and repair of damagedtissues and/or cells. When used to promote the regeneration of diseasedand/or damaged tissue the homeopathic complex can treat multipleconditions. Firstly, the homeopathic complex can treat a multitude ofskin conditions including but not limited to general infection,inflammation, pyrexia, wound healing, skin restoration and repair. Itcan also treat a very wide range of skin disorders such as eczema,purities, sun damage, wrinkles, cracked skin, warts, burns such as sun,heat radiation and chemical burns, piles in humans. Thus, thehomeopathic complex can speed the repair/healing of diseased, damaged,wound or incised tissue deriving from wounds, cuts, cracks, grazes,bites, ulcers. Such damaged tissue may be septic, indolent(non-healing), decubitus (bedsores and pressure damaged skin), recurrentor reopening. Furthermore, the homeopathic complex may be used in thetreatment of burns including heat, radiation including sun, x-raytreatment and prevention, chemical and/or friction/work blisters.Additionally, the homeopathic complex may be used in tissue regenerationin, for example, grafting such as skin grafting or fracture repair.

The homeopathic complex according to the present invention has manyadvantageous properties including safety, speed of action, ease of useand efficacy. These advantages are outlined in the Example sectionbelow.

The homeopathic complex lacks toxicity and associated side effects. Itis well tolerated and is compatible with many conventionalpharmaceuticals. It provides for a rapid response time and is highlyeffective. It can be delivered in multiple formats from topical to oralto parenteral and there are minimal treatment requirements whichincrease patient compliance and enhancing successful outcomes.Furthermore, it provides for a consistent response and action across allspecies and across a wide range of conditions or even types of the samecondition

It will be understood that Core A provides the general anti-infectiveand/or repair/re-growth activity. However, Core A may be supplemented bythe addition of further homeopathic complexes. There are three othergeneral core groups of homeopathic complexes which may be added to CoreA to provide for additionally functionality and to improve efficacy.These are homeopathic complexes which will be known as Core B, Core Cand Core D throughout the specification and examples. The addition ofCores B to D can increase efficacy and be used to tailor the homeopathiccomplex to the specific application needed.

Core B ingredients are involved in the promotion of tissue healing.

Ideally Core B comprises a homeopathic tincture or dilutions thereofderived from the following ingredients:

-   -   the Ranunculacea family, preferably the Aconite Family or        Aconitine, more preferably Aconite napellus [Acon];    -   the Compositae family, preferably Arnica montana [Arn]; Bellis        perennis [Bell-p];    -   Calendula Offcinalis [Calen]; Chamomilla Matricaria [Cham];        Millefolium achillea [Mill];    -   Carduus Marianus; and/or Echinacea, preferably Echinacea        angustifolia [Echi];    -   Echinacea purpurea [Echi-p];    -   the Solanacea family, preferably Belladonna [Bell];    -   Arsenicum, preferably Arsenicum iodatum [Ars-i] and/or Arsenicum        Album;    -   Bryonia alba [Bry];    -   Hamamelis virginiana [Ham];    -   Hypericum Perforatum [Hyper];    -   Ledum palustre [Led];    -   Phytolacca decandra [Phyt];    -   The Anacardiacae family preferably Rhus Toxicodendron [Rhus-T.];    -   The Rutaceae family preferably Ruta Graveolans [Ruta];    -   Stellaria media [Stel]; and/or    -   Symphytum officinale [Symph].

According to a preferred embodiment, Core B comprises a homeopathictincture or dilutions thereof of the following:

-   -   Aconite napellus;    -   Arnica montana;    -   Arsenicum iodatum;    -   Belladonna;    -   Bellis perennis;    -   Bryonia alba;    -   Calendula Officinalis;    -   Echinacea angustifolia;    -   Echinacea purpurea;    -   Hamamelis virginiana;    -   Hypericum Perforatum;    -   Ledum palustre;    -   Millefolium achillea;    -   Phytolacca decandra;    -   Rhus Toxicodendron;    -   Ruta Graveolans; and/or    -   Symphytum officinale.

The combination of the ingredients in Core A and Core B provides ageneral anti-infective homeopathic composition for use in the treatmentof general infections/sepsis.

Optional ingredients which may be included in Core B are ThujaOccidentalis [Thuj], Chamomilla Matricaria [Cham], Stellaria media[Stel] and/or the Sulphurs, preferably Sulphur [Sulph]. A furtheroptional ingredient for Core B is Graphites naturalis [Graph].

Additional ingredients which may be added to Core B are Urtica urens[Urt-u] (equivalent to Urtica dioica), Apis mellifica [Apis],Umbelliferae preferably Conium maculatum [Con] and/or Gunpowder [Gunp].

Core C ingredients function as constitutional modifiers and work forcertain types of individuals boosting their response to treatment. Forexample, Calc Carb boosts the health of large boned heavy often flabbyindividuals while Phosphorus helps lean thin high energy outgoingindividuals. This is particularly important when tailoring the treatmentto the treatment of groups e.g. mastitis in a dairy herd will tendtoward the lean side while a beef herd would tend toward the heavy side.The skilled homeopathic practitioner would be able to determine theappropriate remedies to administer from the following groups.

Core C comprises constitutional modifiers preferably selected from thefollowing homeopathic tincture or dilutions thereof of:

-   -   The Arsenicums, preferably Arsenicum album [Ars];    -   The Barytas and Cabonicums, preferably Baryta carbonica [Bar-c]        and/or Kali Carbonicum;    -   Carbo vegetabilis [Carb-v];    -   The Calcareas, preferably Calcarea carbonica [Calc]; Calcarea        fluorica [Calc-f] and/or Calcarea phosphorica [Calc-p];    -   Gelsemium sempervirens [Gels];    -   Iodium purum [lod];    -   The Kalis, preferably Kali iodatum [Kali-i] and/or Kali        Carbonicum Lacs, preferably Lac caninum [Lac-c]; Lac vaccinum        defloratum (skimmed) and/or Lac Vaccinum (cow);    -   Lycopodium clavatum [Lyc];    -   The Natrums and Muriatricums, preferably Natrum Mur Nux vomica        [Nux-v];    -   Phosphorus, preferably Phosphorus [Phos] and/or Ferrum Phos;    -   the Ranunculacea family, preferably Pulsatilla nigricans [Puls]        and/or Staphysagria [Staph];    -   Sabal serrulata [Sabal];    -   Sepia succus [Sep]; and/or    -   Zincums preferably Zincum metallicum [Zinc].

Core C may also comprise remedies for severe septic infection selectedfrom a homeopathic tincture or dilutions thereof of Baptisia tinctoria[Bapt] and/or Pyrogen [Pyrog].

Core C may also comprise remedies for blood in milk selected from ahomeopathic tincture or dilutions thereof of Bufo rana [Bufo] and/orIpecacuanha [Ip].

Core C may also comprise a homeopathic tincture or dilutions thereof ofAstragalus membranaceus [Astra-mem].

Core D functions as anti-puritic/anti-inflammatory ingredients. Whenused in combination with any of the other Cores, this care providesadditional anti-puritic/anti-inflammatory functionality of thehomeopathic core. Core D comprises a homeopathic tincture or dilutionsthereof of the following ingredients:

-   -   Adrenalin [Adren];    -   Aesculus hippocastanum [Aesc];    -   Alfalfa;    -   Aurums;    -   The Antimoniums, preferably Antimonium Tart    -   Berberis Vulgaris;    -   Cactus Grandiflora;    -   Caladium seguinum [Calad];    -   Cantharis vesicatoria [Canth];    -   Carduus Marianus;    -   Cocculus indicus [Cocc];    -   Chelidonium;    -   China officinalis;    -   Chionanthus virginica;    -   Drosera rotundifolia;    -   Equisetum hyemale;    -   Euphrasia:    -   Galium Aprine;    -   Grindelia (the Compositae family);    -   Histaminium (Histamine) [Hist];    -   Hydrastis canadensis [Hydr];    -   Lappa Articum (the Compositae family);    -   Lavender [Lav-v.];    -   Lobelia inflata;    -   Mezereum [Mez];    -   Nitric acid [Nit-ac];    -   Paeonia Officinalis [Paeon];    -   Prednisolone [Predni.];    -   Ranunculus bulbosus [Ran-b];    -   Rumex crispus [Rumx];    -   Solidago virgaurea;    -   Strophantus hispidus (the Compositae family);    -   Taraxacum officinale (the Compositae family);    -   Triticum Repens;    -   The Stannums preferably Stannum Met;    -   Thiosinaminum [Thiosin];    -   Uva Ursi;    -   Veratrum Album;    -   Cuprum Met; and/or    -   Sol [Sol].

Advantageously, Cores D when administered with any or all of Cores A toC can be used as an anti-itch treatment, pile treatment, stroketreatment, wart treatment, scar treatment, anti-wrinkle treatment. CoreD may act as an anti-pyretic, anti-inflammatory and/or analgesic. Forexample, Thiosinaminum [Thiosin] is used to treat scarring (similar tosilica and graphites) and Sol [Sol] is used to treat sunburn. Many formsof application may be contemplated. In addition, as with otherembodiments of the invention, the potency can be altered depending onthe end use.

Furthermore, the homeopathic complex of the present invention, asdefined in cores A to D above, may also comprise nosodes. Nosodes arehomeopathic remedies that are made from the specific products of aparticular disease. This can be tissue containing the actual diseaseagents or tissue affected by those agents. Sometimes nosodes are madefrom vaccines containing the organisms. The nosodes are prepared in adiluted and potentized form just like all other homeopathic medicine.There is no potential for an animal to become infected with a givendisease agent from a nosode because of the pharmaceutical process thatoccurs which dilutes and inactivates any viable organisms, particularlywhen manufactured using the Hahnemannian method and they are used at 30cand above. Nosodes are ideally selected from Tuberculinum bovinum,Tuberculinium aviaire, Staphylococcus aureus, Strepococcus,Corynebacterium, E. Coli, Colibacillinum, Bacillinum and/or Medorrhinum.

As expanded on above in relation to Core A, an important aspect of thepresent invention is the potency of the homeopathic complex.Specifically, the homeopathic complex may be provided at differentpotency levels in order to work in different areas and on differentconditions. Thus, changing the potency, by dilution and succession, willgive a homeopathic complex with a different mode of action. Thus, asignificant advantage of the present invention is that both thehomeopathic ingredients of Cores A to D can be combined in differentways and the potency can be altered. Different combinations of Cores anddifferent potencies will result in a homeopathic complex used fordifferent conditions.

The invention will now be described in relation to specific embodimentsof the invention and their end uses.

According to a one specific embodiment of the invention, there isprovided a general anti-infective homeopathic composition comprising ahomeopathic tincture or dilutions thereof of:

Hepar Sulph, Lachesis, Merc, Sil; and

Aconite napellus; Arnica montana; Arsenicum iodatum; Belladonna; Bellisperennis; Bryonia alba; Calenula Offcinalis; Chamomilla Matricaria;Echinacea angustifolia; Echinacea purpurea; Graphites naturalis;Hamamelis virginiana; Hypericum Perforatum; Ledum palustre; Millefoliumachillea; Phytolacca decandra; Rhus Toxicodendron; Ruta Graveolans;Stellaria media; Sulphur; Symphytum officinale; and Thuja Occidentalis.

Thus, the general anti-infective healing composition comprises ahomeopathic tincture or dilutions thereof of Core A, Core B, Graphites,Sulphur, Thuja, Chamomilla and Stellaria.

Optional ingredients which may be included are Conium maculatum and/orGunpowder (depending on Regulatory constraints).

Each ingredient is ideally present from 0.1 to 20% v/v based on thevolume of the total composition. Ideally, each ingredient is present inequal ratios/proportions.

Ideally, the potency of each ingredient is in the low potency range frommother tincture to approximately 18×/9c, preferably 12×/6c. This potencyis ideal for topical administration, in the form of for example, atopical cream, gel or liquid. Optionally, this homeopathic compositionmay be given in a high potency and used internally as a generalanti-infective healing composition. Applicants have found the besteffects are when the composition is administered in low potency foradministration.

According to a preferred embodiment, this homeopathic composition isformulated as a topical cream. A non-active base is ideally used,comprising lanolin, petroleum and mineral oil. Such as base couldcomprise, for example, approximately 15 to 35%, preferably 25% lanolin,approximately 40 to 60%, preferably 50% petroleum with 15 to 25%,preferably 25% mineral oil and would be ideal for use in cold climates.It will be appreciated that any other non-active bases known may beused.

The following table outlines suitable potency ranges for each of theingredients when used in a topical general anti-infective healingformulation.

It will also be understood that some homeopathic ingredients may beadministered as a mother tincture, however, as explained before, forRegulatory reasons in some countries some homeopathic ingredients maynot be administered as a mother tincture and must be diluted to 2×,preferably 6× or 8× or higher for administration. These are indicated onthe table below.

Effective [Short Preferred Range Example Final dilution Remedy form] forTopical Use Potency in Cream Hepar Sulphuris [Hep-s] Range 2x-12x/6c 3x*4x Lachesis [Lach] Range 8x-12x/6c 8x 9x Mercurius Solubilis [Merc-s]Range 6x-12x/6c 6x 7x Silica [Sil] Range 2x-12x/6c 3x* 4x AconitumNapellus [Acon] Range 2x-12x/6c 3x* 4x Arnica Montana [Arn] RangeMT-12x/6c 3x* 4x Arsenicum Iod [Ars-i] Range 6x-12x/6c 6x 7x Belladonna[Bell] Range 2x-12x/6c 3x* 4x Bellis Perenis [Bell-p] Range MT-12x/6c3x* 4x Bryonia Alba [Bry], Range MT-12x/6c 3x* 4x Calenula Offcinalis[Calen] Range MT-12x/6c 3x* 4x Chamomilla Matricaria [Cham] RangeMT-12x/6c 3x* 4x Echinacia augustifolia [Echi-a] Range MT-12x/6c 3x* 4xEchinacia Purpurea [Echi-p] Range MT-12x/6c 3x* 4x Graphites naturalis[Graph] Range 8x-12x/6c 8x 9x Hamamellis Virginiana [Ham] RangeMT-12x/6c 3x* 4x Hypericum Perforatum [Hyper] Range MT-12x/6c 3x* 4xLedum [Led] Range MT-12x/6c 3x* 4x Millefolium [Mill] Range MT-12x/6c3x* 4x Phytolacca [Phyt] Range 6x-12x/6c 6x 7x Rhus Toxicodendron[Rhus-t] Range MT-12x/6c 3x* 4x Ruta Graveolans [Ruta] Range MT-12x/6c3x* 4x Stellaria Media [Stel] Range MT-12x/6c 3x* 4x Sulphur** [Sulph]Range MT-12x/6c 4x 4x Symphytum [Symph] Range MT-12x/6c 3x* 4x ThujaOccidentalis [Thuja] Range MT-12x/6c 3x* 4x *these potencies are idealfor use in the USA. Some minor adjustments to the potencies may beneeded for Europe where for Regulatory reasons 3x potencies requireadditional tests and must be 4x or higher for simplified registrations.Again, this will largely be determined in the country of interest basedon Regulatory constraints. **As stated above, Sulphur for example is notsoluble below 4x but can be mixed into a cream as sulphur powder thathas been titurated with lactose to form a titurate. Arsenicum Iod,Sulphur, Silica, Graphite and Hepar Sulp are also insoluble and formtiturates not tinctures. Lachesis is best prepared initially inglycerine (to preserve the protein activity of the venom) as it can bedenatured by both alcohol and lactose.

According to this embodiment of the invention, to make an anti-infectivecream, each ingredient is made according to the potency range above andthis is done by different methods depending on whether it is a tinctureor titurate. A titurate refers to the insoluble homeopathic ingredients,such as Arsenicum lod, Sulphur, Silica, Graphite, Hepar Sulp, Lachesisetc, which are diluted and potentised by grinding with lactose. Atincture is as defined previously and is diluted and potentised in theusual manner by sucussion in an alcohol and water premix. The tinctureand titurates are then combined with each other and the base cream.These comments about tincture and titurates are relevant to allembodiments/compositions of the invention.

Each ingredient is ideally combined in equal proportions in a non-activecream base. Ideally, the combined ingredients are combined with thecream from approximately 1 to 10% w/v based on the total weight of thefinal homeopathic composition. Preferably, the combined ingredients arecombined with a cream at from 3 to 6% w/v based on the total weight ofthe final homeopathic composition.

According to a more specific embodiment of the invention, there isprovided a general anti-infective homeopathic composition which can beused in the treatment of mastitis.

Mastitis is initially caused by microbial infection through damagedskin. In particular, mastitis has a tremendous economic importance forthe dairy industry as the present antibiotic therapies reduce usablemilk yield. Thus, alternative therapies to conventional antibiotictherapies are under evaluation. Common causal microorganisms found inmastitis include:

-   -   Staphylococcus aureus;    -   Staphylococcus albus;    -   Streptococcus species e.g. agalactia, uberis, dysgalactia;    -   Escherichia coli;    -   Salmonella species;    -   Mycobacterium tuberculosis; and/or    -   Fungal mastitis e.g. Candida albicans and Cryptococcus        neoformans.

Such a mastitis treatment ideally comprises a homeopathic tincture ordilutions thereof of:

-   -   Hepar Sulphuris Calcareum, Lachesis, Merc Sol, Silicea; and    -   Aconitum Napellus, Arnica Montana, Arsenicum lod, Belladonna,        Bellis Perenis, Bryonia Alb, Calenula Offcinalis, Chamomilla        Matricaria, Conium maculatum, Echinacia augustifolia, Echinacia        Purpurea, Graphites, Hamamellis Virginia, Hypericum Perforatum,        Ledum, Millefolium, Phytolacca decandra, Ruta Graveolans, Rhus        Toxicodendron, Stellaria Media, Sulphur, Symphytum, Urtica Urens        and Thuja Occidentalis.

Essentially, this mastitis treatment comprises Core A and Core B plusChamomilla Matricaria, Stellaria Media, Graphites, Sulphur and Thuja,Conium and Urtica.

Gunpowder is an optional homeopathic ingredient for this homeopathiccomposition and its use depends on Regulatory constraints in theapplicable country.

The homeopathic complex of the present invention may be use to treatelevated Somatic Cell Counts, to prevent Mastitis and in the treatmentof mammary hypertrophy and other hypertrophic conditions.

Again, each ingredient is ideally present from 0.1 to 20% v/v based onthe volume of the total composition. Ideally, each ingredient is presentin equal ratios/proportions.

Ideally, the potency of each ingredient is in the low potency range frommother tincture to approximately 18×/9c, preferably 12×/6c. This potencyis ideal for topical administration, in the form of for example, atopical cream, gel or liquid. Optionally, this homeopathic compositionmay be given in a high potency and used internally as a mastitistreatment composition. Applicants have found the best effects are whenthe composition is administered in low potency for administration.

According to a preferred embodiment, this homeopathic composition isformulated as a topical cream. A non-active base is ideally used,comprising lanolin, petroleum and mineral oil. Such as base couldcomprise, for example, approximately 15 to 35%, preferably 25% lanolin,approximately 40 to 60%, preferably 50% petroleum with 15 to 25%,preferably 25% mineral oil and would be ideal for use in cold climates.It will be appreciated that any other non-active bases known may beused.

The following table outlines suitable potency ranges for each of theingredients when used in a topical formulation for mastitis treatment.

Preferred Effective Final Potency Range Preferred dilution in Remedy forTopical Use Potency Cream Hepar Sulphuris 2x-12x/6c 3x* 4x Lachesis8x-12x/6c 8x 9x Mercurius Solubilis 6x-1x/6c 6x 7x Silica[Sil] 2x-1x/6c3x* 4x Aconitum Napellus 2x-12x/6c 3x* 4x Arnica Montana MT-12x/6c 3x*4x Arsenicum Iod 6x-12x/6c 6x 7x Belladonna 2x-12x/6c 3x* 4x BellisPerenis MT-12x/6c 3x* 4x Bryonia Alb MT-12x/6c 3x* 4x CalenulaOffcinalis MT-12x/6c 3x* 4x Chamomilla Matricaria MT-12x/6c 3x* 4xConium maculatum MT-12x/6c 8x 9x Echinacia augstofolia MT-12x/6c 3x* 4xEchinacia Purpurea 8x-12x/6c 3x* 4x Graphites MT-12x/6c 8x 9x GunpowderMT-12x/6c 3x* 4x Hamamellis Virginia MT-12x/6c 3x* 4x HypericumPerforatum MT-12x/6c 3x* 4x Ledum 6x-12x/6c 3x* 4x Millefolium MT-12x/6c3x* 4x Phytolacca decandra 6x-12x/6c 6x* 7x Ruta Graveolans MT-12x/6c3x* 4x Rhus Toxicodendron MT-12x/6c 3x* 4x Stellaria Media MT-12x/6c 3x*4x Sulphur** MT-12x/6c 3x* 4x Symphytum MT-12x/6c 3x* 4x ThujaOccidentalis MT-12x/6c 3x* 4x Urtica Urens MT-200c 30c 30c *thesepotencies are ideal for use in the USA. Some minor adjustments to thepotencies may be needed for Europe where for Regulatory reasons 3xpotencies require additional tests and must be 4x or higher forsimplified registrations. Again, this will largely be determined in thecountry of interest based on Regulatory constraints. **As stated above,Sulphur for example is not soluble below 4x but can be mixed into acream as sulphur powder that has been titurated with lactose to form atiturate. Arsenicum Iod, Sulphur, Silica, Graphite and Hepar Sulp arealso insoluble and form titurates not tinctures. Lachesis is bestprepared initially in glycerine (to preserve the protein activity of thevenom) as it can be denatured by both alcohol and lactose.

Optionally, nosodes from Tuberculinum bovinum, Tuberculinium aviaire,Staphylococcus aureus, Strepococcus, Streptococcus uberisCorynebacterium, E. Coli, Colibacillinum, Bacillinum and/or Medorrhinummay be used. Ideally, such nosodes are present in a potency range from6× to 1M, preferably from approximately 6×-12×/6c. It will be understoodthat any nosode of any pathogen or pathological material including thoseinvolved in the condition to be treated may be used.

A further anti-infective mastitis treatment comprising Core A; Core Bplus Stellaria media, Chamomilla matriaca, Sulphur and conium; and CoreC without Arsenicum album, Gelsemium, Lac vaccinum and Staphlysagria.Ferrum Phos, Natrum Mur, Kali Carbonicum. This mastitis treatment wasused in Example 10.

PREFERRD PREFERRED POTENCY PREFERRED CONCENTRATION CONCENTRATION REMEDYRANGE POTENCY RANGE Vol/Vol % Aconitum napellus 4x TO12C 6C .1 to 20%1.15% Aconitum napellus 12c TO 197c 30C .1 to 20% 1.15% Aconitumnapellus 198c TO 10M 200C .1 to 20% 1.15% Apis Mel 6c 6C TO 1M 6C .1 to20% 0.69% Arnica Montana 6x TO 27C 6C .1 to 20% 0.69% Arnica Montana 27cTO 1M 30C .1 to 20% 0.69% Astragalus 6x TO 27C 6C .1 to 20% 0.69%Astragalus 27c TO 1M 30C .1 to 20% 0.69% Arsencium Iod 6x to 24x/12c 8x.1 to 20% 0.69% Baptista 27c TO 1M 30C .1 to 20% 1.15% Belladonna 6c TO100c 30c .1 to 20% 2.29% Belladonna 101c TO 997C 200c .1 to 20% 2.29%Belladonna 998C to 9997C 1M .1 to 20% 2.29% Bellis Perenis 6x TO 27C 6C.1 to 20% 1.15% Bellis Perenis 27c TO 1M 30C .1 to 20% 1.15% Bryonia 4xTO12C 6C .1 to 20% 2.29% Bryonia 12c TO 197c 30C .1 to 20% 2.29% Bryonia198c TO 10M 200C .1 to 20% 2.29% Bufo 6x TO 27C 6C .1 to 20% 0.69% Bufo27c TO 1M 30C .1 to 20% 0.69% Calc Carb 6x TO 27C 6C .1 to 20% 1.15%Calc Carb 27c TO 1M 30C .1 to 20% 1.15% Calc Phos 6x TO 27C 6C .1 to 20%1.15% Calc Phos 27c TO 1M 30C .1 to 20% 1.15% Calc Fluor 6x TO 27C 6C .1to 20% 0.69% Calc Fluor 27c TO 1M 30C .1 to 20% 0.69% Calendula 6c 6x TO1M 6C .1 to 20% 0.69% Carbo Veg 6x TO 27C 6C .1 to 20% 2.29% Carbo Veg27c TO 1M 30C .1 to 20% 2.29% Chamomilla 6x TO 27C 6C .1 to 20% 0.69%Chamomilla 27c TO 1M 30C .1 to 20% 0.69% Conium 6x TO 27C 6C .1 to 20%0.69% Conium 27c TO 1M 30C .1 to 20% 0.69% Echinacea Angustifolia 6C TO1M 6C .1 to 20% 0.69% Echinacea purpurea 6C TO 1M 6C .1 to 20% 0.69%Hammamelis 6x TO 1M 30c .1 to 20% 0.69% Hepar Sulph 30C TO 200C 200c .1to 20% 2.29% Hepar Sulph 201C to 9997C 1M .1 to 20% 2.29% Hepar Sulph9999C TO 50M 10M .1 to 20% 2.29% Hypericum 6x TO 27C 6C .1 to 20% 0.69%Hypericum 27c TO 1M 30C .1 to 20% 0.69% Iodium 6x TO 27C 6C .1 to 20%0.69% Iodium 27c TO 1M 30C .1 to 20% 0.69% Ipecac 6x TO 27C 6C .1 to 20%0.69% Ipecac 27c TO 1M 30C .1 to 20% 0.69% Kali Iod 6x TO 1M 6C .1 to20% 0.69% Lac Caninum 6x TO 1M 30c .1 to 20% 2.29% Lac Bovinum 6x TO 1M30c .1 to 20% 2.29% Lachesis 6x to 12c/24x 6c .1 to 20% 1.15% Lachesis12c TO 197c 30c .1 to 20% 1.15% Lachesis 198c TO 10M 200c .1 to 20%1.15% Ledum 6x TO 27C 6C .1 to 20% 0.69% Ledum 27c TO 1M 30C .1 to 20%0.69% Lycopodium 6x TO 27C 6C .1 to 20% 0.69% Lycopodium 27c TO 1M 30C.1 to 20% 0.69% Merc Sol 30C TO 200C 200c .1 to 20% 1.15% Merc Sol 201Cto 9997C 1M .1 to 20% 1.15% Merc Sol 9999C TO 50M 10M .1 to 20% 1.15%Nux Vomica 6x TO 27C 6C .1 to 20% 0.69% Nux Vomica 27c TO 1M 30C .1 to20% 0.69% Phosphorus 6x TO 1M 30c .1 to 20% 1.15% Phytolacca decandra 6xto 12c/24x 6c .1 to 20% 2.29% Phytolacca decandra 12c TO 197c 30c .1 to20% 2.29% Phytolacca decandra 198c TO 10M 200c .1 to 20% 2.29%Pulsatilla 6x TO 1M 30c .1 to 20% 1.15% Pyrogen 30C TO 10M 1M .1 to 20%1.15% Rhus toxicodendron 6x to 12c/24x 6c .1 to 20% 0.69% Rhustoxicodendron 12c TO 197c 30c .1 to 20% 0.69% Rhus toxicodendron 198c TO996c 200c .1 to 20% 0.69% Rhus toxicodendron 997C TO 9997C 1M .1 to 20%0.69% Ruta Grav 6x to 12c/24x 6c .1 to 20% 0.69% Ruta Grav 12c TO 197c30c .1 to 20% 0.69% Ruta Grav 198c TO 10M 200c .1 to 20% 0.69% Sabal 6xTO 27C 6C .1 to 20% 0.69% Sabal 27c TO 1M 30C .1 to 20% 0.69% Sepia 6xTO 27C 6C .1 to 20% 0.69% Sepia 27c TO 1M 30C .1 to 20% 0.69% Silica 6cTO 100c 30c .1 to 20% 2.29% Silica 101c TO 997C 200c .1 to 20% 2.29%Silica 998C TO 9997C 1M .1 to 20% 2.29% Stellaria Media 6x TO 1M 30c .1to 20% 0.69% Suphur 6x TO 1M 30c .1 to 20% 2.29% Symphytum 6x TO 1M 30c.1 to 20% 0.69% Urtica 6x TO 1M 30c .1 to 20% 0.69% Zincum Met 4x TO12C4c .1 to 20% 0.69% Zincum Met 6x TO 1M 30c .1 to 20% 0.69% 100.00%

The composition as defined above is ideal for internal use and is in theC potency range.

Ideally, this homeopathic composition is in a form suitable for internaluse, for example a liquid with excipients being alcohol and water.

Optionally, nosodes are combined with this homeopathic mastitistreatment composition. Suitable nosodes are outlined in the followingtable.

CONCEN- PREFERRED TRATION POTENCY EXAMPLE Vol/Vol % NAME OF REMEDY RANGEPOTENCY RANGE Tuberculinum Bovinum 30C TO 1M 30c .1% TO 20%Tuberculinium Aviaire 30C TO 1M 30c .1% TO 20% Staphylococcus Aureus 30CTO 1M 30c .1% TO 20% Strepococcus 30C TO 1M 30c .1% TO 20% StrepococcusMix 30C TO 1M 30c .1% TO 20% Corynebacterium 30C TO 1M 30c .1% TO 20% E.Coli (ColibacillinuM) 30C TO 1M 30c .1% TO 20% E. Coli 30C TO 1M 200c.1% TO 20% Bacillinum 30C TO 1M 30c .1% TO 20% Medorrhinum 30C TO 1M 30c.1% TO 20%

Ideally, the nosodes are added in equal proportions/ratios.

According to another embodiment of this aspect of the invention, aneffective mastitis treatment comprises the use of the homeopathiccomposition defined above for internal use administered concurrentlywith the previously defined topical mastitis treatment.

According to a more specific embodiment of the invention, there isprovided a general anti-infective homeopathic composition used in thetreatment of trauma or shock comprising a homeopathic tincture ordilutions thereof of the following ingredients:

Hepar Sulphuris Calcareum, Lachesis, Merc Sol, Silicea; and

Aconite;

Arsencium lod;

Arnica Montana;

Apis;

Belladonna;

Bellis Perennis;

Bryonia;

Calendula;

Cantharis;

Carbo Veg;

Crategus;

Echinacea Augustifolia;

Echinacea Purpura;

Ferrum Phos;

Gelsemium;

Hammamellis;

Hypericum;

Laurocerasus;

Ledum;

Millefolium;

Nux Vomica;

Phytolacca;

Rhus Tox;

Ruta Gray;

Symphytum; and

Staphysagria.

Essentially, this homeopathic composition comprises Core A; Core B withChamomilla matricaria and Stellaria media, Sulphur, Apis and Urtica;Core C ingredients Carbo veg, Gelsemium, Nux Vomica and Phos; andCantharis, Laurocerasus, Crategus and Ferrum phos. The following tableoutlines suitable potency ranges for each of the ingredients.

REMEDY Preferred Range Preferred Potency Aconite 30C-10M 1M Apis 30C-10M1M Arnica Montana 30C-10M 1M Arsencium Iod 6x to 24x/12c 8x Belladonna30C-10M 1M Bellis Perennis 30C-10M 1M Bryonia 30C-10M 1M Calendula30C-10M 1M Cantharis 30C-10M 1M Carbo Veg 30C-10M 1M Causticum 28C TO10M 30c Conium 28C TO 10M 30c Crategus MT-24x/12c 4x EchinaceaAnugustifolia 30C-10M 1M Echinacea Purpura 30C-10M 1M Ferrum Phos 6x to24x/12c 12x Gelsemium 30C-10M 1M Hammamellis 30C-10M 1M Hepar Sulph30C-10M 1M Hypericum 30C-10M 1M Lachesis 30C-10M 1M LaurocerasusMT-24x/12c 4x Ledum 30C-10M 1M Merc Sol 30C-10M 1M Millefolium 30C-10M1M Nux Vomica 30C-10M 1M Phosphorus 30C-10M 200c Phytolacca 30C-10M 1MRhus Tox 30C-10M 1M Ruta Grav 30C-10M 1M Silica 30C-10M 1M Sulphur6x-10m 30c Staphysagria 30C-10M 1M Symphytum 30C-10M 1M Urtica 28C TO10M 30c chamomilla matrica 30-10m 1m stellaria 28c-10m 30c

Ideally, this homeopathic composition is in a form suitable for internaluse, for example a liquid with excipients being alcohol and water.

The homeopathic ingredients are combined from approximately 0.1 to 20%v/v based on the total volume of the final homeopathic composition. Eachingredient is ideally combined in approximate equal proportions (1:1ratio) in the liquid excipient.

It will be understood that the homeopathic complexes of the presentinvention may be used in the both human medical and veterinaryapplications and are trans-species in action. Indeed, as shown in theExamples, the homeopathic complexes work in a wide variety of species,from companion animal (e.g. canines, felines to exotic parrot etc) tofarm animals (e.g. equines and bovines etc) and to humans to name a few.

It will be understood that the general mode of action common to all thehomeopathic complexes of the present invention, is the treatment ofmicrobial infections and/or the repair and re-growth of damaged cells ortissue.

Specific applications of the homeopathic composition according to theinvention, include but are not limited to treatment of the followingconditions:

-   -   Wound treatment;    -   Fracture treatment;    -   Dermatitis, including photo-dermatitis;    -   Sun burn;    -   MRSA Infection;    -   Mastitis;    -   Stroke;    -   Pneumonia;    -   Hepatitis;    -   Nephritis; and/or    -   Detoxification.

Some specific non-limiting uses of the homeopathic complex are outlinedas follows.

The homeopathic complex may be used in the treatment of various skinconditions including eczema and the like. Advantageously, Applicantshave found that scars are either prevented or minimized. Thus, thehomeopathic complex may be used as a scar treatment.

The homeopathic complex may also be used in the treatment of mastitis,both acute and chronic. Mastitis is a widespread condition in manyanimals, in particular cattle. Conventional treatments for mastitisinvolve the use of antibiotics which is not desirable for commercialmilk production. Any treatment which results in the reduction of the useof antibiotics would be advantageous for commercial milk production incows. Thus, the generation of a new therapy for the treatment ofmastitis which does not involve antibiotics is desirable.

The homeopathic complex may also be used for detoxification and such acomposition would generally comprise Core A and some of Cores B, C andD.

According to another aspect of the present invention, the homeopathiccomplex can be used as a cosmetic skin preparation. For example it maybe used as an anti-wrinkle cream in the repair and or regeneration ofskin cells.

Ideally, the homeopathic complex is manufactured according to acompetent homeopathic pharmacopeia such as the German, US, UK, EU and/orFrench Homeopathic Pharmacopeias. Preferably, the homeopathic complexesare provided in a potency range from 1× to 12×, more preferably from 3×to 12× for the purposes of analytical traceability (ChurchillLivingstone's International Dictionary of Homeopathy Edited by JeremySwayne (2000) page 193, 1st Edition). Although, it will be understoodthat any potency from homeopathic tincture upwards can be used providedthat the dangers of toxicity with very low potencies or tinctures aremanaged and all Official Regulatory conditions are met.

Homeopathic complexes are generally prepared in liquid carrier solutions(as a tincture) but may also be extracted in, for example, lactose bytrituration and may thereafter be prepared in various delivery forms.For example, the extracted material of the homeopathic ingredient may beextracted in liquid form, using an alcohol and water solvent. This isthen followed by comminution, percolation, maceration and squeezingtechniques. When extracted in liquid form the resulting solution cancontain anywhere from one part drug to three parts mother tincturealthough this strength can vary from 10 to 50% depending on themonograph used. What makes a tincture truly homeopathic is theadditional dilution process to where the final tincture represents adilution of 1:10 of the drug in effect a 1× dilution. Titurates ofinsoluble homeopathic ingredients may also be made. Extraction of thehomeopathic ingredient by tituration may take place using lactose toresult in a solid or powder extract done up to 3c or third centesimaldilution. The homeopathic tincture or titurate may then be combined witha base for use as a topical preparation or be used directly as a liquidoral preparation. Alternatively, it may be sprayed or impregnated ontovarious solid mediums, such as a tablet.

All the complexes according to the present invention may be used fortopical including eye drops, oral, transdermal, implanted, suppository,or parenteral administration in a wide variety of forms such as gels,spray, liquids, powders, tablets, pillules, lotions, liniments,ointments to give just some examples. It will be understood that thehomeopathic complex is made in the usually homeopathic manner accordingto homeopathic guidelines. It may then be administered as it is, or as ahomeopathic dilution thereof. It may be administered in different waysby combining the complex with a delivery means, such as a cream or sprayfor topical use or a tablet for oral administration etc.

According to one specific embodiment of this aspect of the invention thehomeopathic complex is in the form of an oral preparation, such as a drydose form including a powder or tablet. Preferably, the homeopathiccomplex is provided in the form of a dosage unit form selected from agroup consisting of tablets, capsules, pellets, gel caps, pills,pillules, globules, granules, crystals and suppositories. For example,tablets comprising lactose and sucrose may be used.

Alternatively, the homeopathic complex according to this aspect of theinvention may be in the form of a liquid preparation, such as a syrup orpaste, spray or drops. Delivery of the liquid preparations may be in theform of injections, eyedrops, eardrops, nasal sprays, inhalers ordiffusers.

According to another embodiment of this aspect of the invention thehomeopathic complex may be in the form of a topical preparation such asan ointment, cream, lotion, oil, liniment, liquid and gel, such as ahydrophilic ointment.

Daily to twice or thrice administration of the homeopathic complex for aperiod of days is contemplated. It may be applied topically as needed,orally for daily dosage in unit dosage form or in liquid drops.

Conventional pharmaceutical excipients or cosmetic excipients suitablefor the deliver system used can have the homeopathic complexincorporated into them or the homeopathic complex can be applied to theend product or packaged with the end product.

Pharmaceutical excipients are substances other than thepharmacologically active drug or prodrug which are included in themanufacturing process or are contained in a finished pharmaceuticalproduct dosage form. They are classified by the functions they performin a pharmaceutical dosage form. Principal excipient classifications orfunctions include, but are not limited to the following:

-   -   Binders;    -   Disintegrants;    -   Fillers (diluents);    -   Lubricants;    -   Glidants (flow enhancers);    -   Compression aids;    -   Colors;    -   Sweeteners;    -   Preservatives;    -   Suspensing/dispersing agents;    -   Film formers/coatings; and/or    -   Flavors.

Some, for example, comprise the product's delivery system. Thesetransport the active drug to the site in the body where the drug isintended to exert its action. Others will keep the drug from beingreleased too early in the assimilation process in places where it coulddamage tender tissue and create gastric irritation or stomach upset.Others help the drug to disintegrate into particles small enough toreach the blood stream more quickly and still others protect theproduct's stability so it will be at maximum effectiveness at time ofuse. In addition, some excipients are used to aid the identification ofa drug product. Last, but not least, some excipients are used simply tomake the product taste and look better. This improves patientcompliance, especially in children. Although technically “inactive” froma therapeutic sense, pharmaceutical excipients are critical andessential components of a modern drug product. In many products,excipients make up the bulk of the total dosage form.

Ideally this formulation is provided in a form suitable for topicaladministration. As such, it may be delivered as a topical cream, lotion,gel, ointment, liniment, eyedrops, spray, skin patch/dressing orcombined with a conventional topical medication or skin treatment.

For topical administration, the homeopathic formulation can be combinedinto any commercially available base. For examples, the base maycomprise approximately

Lanolin from approximately 15 to 35%, preferably 25%

Mineral oil from approximately 15 to 35%, preferably 25%

Petroleum from approximately 40 to 60%, preferably 50% at 2 oz/lb.

Alternatively the base may be a silcox base or a non-lanolin non-mineraloil aqueous cream.

In addition, the homeopathic complex may be administered as acombination therapy, for example, at the same time as a conventionalpharmaceutical, e.g. antibiotic, nutritional supplement or food.

In this specification the term “pharmaceutical” or “pharmaceuticalcomposition” covers any chemical or biological substance, synthetic ornon-synthetic which when taken by a subject will alter the function ofthat subject. Such substances ideally are intended for use in thetreatment or prevention of disease in man or other animals. As such thisterm encompass more that conventional drugs or medicines and can alsocover food, medicines, vitamins and minerals in general. Furthermore,the term “pharmaceutical” also the substance however it is made and, assuch, encompasses biopharmaceuticals, biotechnology-derived treatments(including gene therapy) and phytotherapies.

In this specification the term “combination therapy” is used broadly tocover the simultaneous administration of the homeopathic complex and thepharmaceutical composition. As such, the homeopathic tincture may bepackaged separately to the pharmaceutical composition which is providedwith a set of instructions for co-administration. The term “combinationtherapy” also covers the combination of the homeopathic complex with thepharmaceutical composition as a single entity. In this way, thehomeopathic complex may be combined or integrated with thepharmaceutical composition during or after manufacture. For example, thehomeopathic complex when in liquid form may be sprayed onto thepharmaceutical composition. Alternatively, the homeopathic complex maybe provided in liquid or powder form and may simply be combined or mixedwith the pharmaceutical composition during manufacture. In this manner,the pharmaceutical composition acts as a delivery system for thehomeopathic composition.

The co-administration of a conventional drug and a homeopathic accordingto the invention goes against Classical Homeopathic teachings andtechniques. According to Classical/conventional homeopathic teachings,homeopathic complexes must be taken on their own at least 20 minutesafter ingesting any food or drink. On the contrary the present inventiondictates that the homeopathic complex is either part of a combinationtherapy or co-administered with a pharmaceutical composition. This wouldnot be expected in the field of classical homeopathy.

According to another aspect of the invention, there is provided ahomeopathic complex of the invention for use in therapy.

Ideally, the homeopathic complex of the invention is for use in thetreatment or prophylaxis of infection as an anti-infective agent.Specifically, the homeopathic complex of the invention may be used inthe treatment of mastitis. Specifically, the homeopathic complex may beused in the treatment or prophylaxis of MRSA and other type ofmulti-resistant infections. Additionally, the homeopathic complex of theinvention may be used in the regeneration of diseased or damaged tissue.In addition, the homeopathic complex of the invention may be used in thetreatment of skin conditions, including acne, general infection,inflammation, pyrexia, wound healing, skin restoration and repair andskin disorders including eczema, puritis, sun damage, wrinkles, crackedskin warts, burns such as sun, heat and radiation burns and/or piles.The homeopathic complex of the invention may be used in the treatment ofa stroke or as a first aid remedy.

According to another aspect of the invention, there is provided a methodfor the manufacture of a medicament comprising the homeopathic complexof the invention for use in the treatment or prophylaxis of infectionand/or the regeneration of diseased or damaged tissue.

According to yet another aspect of the present invention there isprovided a method for the treatment or prophylaxis of infection and/orthe regeneration of diseased or damaged tissue in a subject comprisingthe steps of administering an effective amount of a homeopathic complexof the invention claimed to a patient in need of such treatment.

The invention will now be described by reference to the followingnon-limiting figures and examples.

EXAMPLES

General Methodology

The general methodology in the following examples, in particular inexamples 1 to 9, was to select patients where recovery was not expecteddespite having been treated with conventional treatments and there wasno other conventional treatment to use. Thus, patients who received thehomeopathic compositions according to the invention were selected asdescribed on the basis of a non-response to conventional therapy.

Materials

Unless otherwise stated, it will be understood that each homeopathicingredient is combined in approximate equal proportions fromapproximately 0.1% to 20% v/v based on the volume to of the totalhomeopathic complex.

Also unless otherwise stated, homeopathic complexes for topical use, inthe forms of creams, are generally in the low potency range, from forexample mother tincture to approximately 18×/9c. For internal use, forexample as a liquid composition, the homeopathic ingredients aregenerally of the high potency range from 30 plus, preferably 200c plus.

Finally and unless otherwise stated, when used as a cream, thehomeopathic complex is generally combined with a base comprisingapproximately 25% Lanolin, approximately 50% approximately Petroleumwith 25% Mineral oil. When used as a liquid the homeopathic complex isgenerally administered in alcohol and water, for example 20% ethylalcohol and 80% purified water or 30-40% glycerine and 70% purifiedwater. Alternative bases and carriers, as expanded in the specificExamples following, include topical antibiotics and Aloe Vera Veterinaryspray.

The following complexes, defined in Cores A to D, were used in theExamples 1 to 9.

Core A Ingredients

Hepar sulphuris calcareum [Hep]; Lachesis muta [Lach]; MercuriusSolubilis [Merc] and Silica [Sil].

These are the essential anti-infective/anti sepsis ingredients. It willbe understood that Lachesis may be replaced or complemented with manysnake or spider remedies which have a similar septic shock profiles e.g.Crotalidae (crotalus Horridalus) and Tarentula Cubensis.

Core B Ingredients

Aconite napellus [Acon]

Arnica montana [Arn]

Arsenicum iodatum [Ars-i]

Belladonna [Bell]

Bellis perennis [Bell-p]

Bryonia alba [Bry]

Calenula Offcinalis [Calen]

Chamomilla Matricaria [Cham]

Echinacea angustifolia [Echi]

Echinacea purpurea [Echi-p]

Graphites naturalis [Graph]

Hamamelis virginiana [Ham]

Hypericum Perforatum [Hyper]

Ledum palustre [Led]

Millefolium achillea [Mill]

Phytolacca decandra [Phyt]

Rhus Toxicodendron [Rhus-T]

Ruta Graveolans [Ruta]

Stellaria media [Stel]

Sulphur [Sulph]

Symphytum officinale [Symph]

Thuja Occidentalis [Thuj]

Additional Core B ingredients, Conium maculatum [Con] and Gunpowder[Gunp], were used in Examples 1 to 9 only.

Core C Ingredients

Arsenicum album [Ars]

Apis mellifica [Apis]

Astragalus membranaceus [Astra-mem.]

Baptisia tinctoria [Bapt]

Bufo rana [Bufo]

Carbo vegetabilis [Carb-v]

Calcarea carbonica [Calc]

Calcarea fluorica [Calc-f]

Calcarea phosphorica [Calc-p]

Gelsemium sempervirens [Gels]

Iodium purum [lod]

Ipecacuanha [Ip]

Kali iodatum [Kali-i]

Lac caninum [Lac-c]

Lac Bovinum Lac Vaccinum (cow)

Lycopodium clavatum [Lyc]

Nux vomica [Nux-v]

Phosphorus [Phos]

Pulsatilla nigricans [Puls]

Pyrogen [Pyrog]

Sabal serrulata [Sabal]

Sepia succus [Sep]

Staphysagria [Staph]

Urtica urens [Urt-u]

Zincum metallicum [Zinc]

Core D Ingredients

Adrenalin [Adren]

Aesculus hippocastanum [Aesc]

Baryta carbonica [Bar-c]

Caladium seguinum [Calad]

Cantharis vesicatoria [Canth]

Cocculus indicus [Cocc]

Histaminium (Histamine) [Hist]

Hydrastis canadensis [Hydr]

Lavender [Lav-v.]

Mezereum [Mez]

Nitric acid [Nit-ac]

Paeonia Officinalis [Paeon]

Prednisolone [Predni.]

Ranunculus bulbosus [Ran-b]

Rumex crispus [Rumx]

Thiosinaminum [Thiosin]

Sol [Sol]

Optional Nosodes

Nosodes are ideally selected from Tuberculinum bovinum, Tuberculiniumaviaire, Staphylococcus aureus, Strepococcus, Corynebacterium, E. Coli,Colibacillinum, Bacillinum and/or Medorrhinum.

The Following Complex was Used in Example 10.

This treatment essentially comprises, Core A, Core B minus graphites,millefolium and thuja and Core C minus Arsenicum, Gelsemium andStaphysagria, plus Conium.

Preferred Actual Preferred Potency Concentration Working Potency OfVol/Vol % Example Name Of Remedy Range Example Range Vol/Vol % Aconitumnapellus 4x TO12C 6C .1% TO 20% 1.15% Aconitum napellus 12c TO 197c 30C.1% TO 20% 1.15% Aconitum napellus 198c TO 10M 200C .1% TO 20% 1.15%Apis Mel 6c 6C TO 1M 6C .1% TO 20% 0.69% Arnica Montana 6x TO 27C 6C .1%TO 20% 0.69% Arnica Montana 27c TO 1M 30C .1% TO 20% 0.69% Astragalus 6xTO 27C 6C .1% TO 20% 0.69% Astragalus 27c TO 1M 30C .1% TO 20% 0.69%Arsencium Iod 6x to 24x/12c 8x .1% TO 20% 0.69% Baptista 27c TO 1M 30C.1% TO 20% 1.15% Belladonna 6c TO 100c 30c .1% TO 20% 2.29% Belladonna101c TO 997C 200c .1% TO 20% 2.29% Belladonna 998C TO 9997C 1M .1% TO20% 2.29% Bellis Perenis 6x TO 27C 6C .1% TO 20% 1.15% Bellis Perenis27c TO 1M 30C .1% TO 20% 1.15% Bryonia 4x TO 12C 6C .1% TO 20% 2.29%Bryonia 12c TO 197c 30C .1% TO 20% 2.29% Bryonia 198c TO 10M 200C .1% TO20% 2.29% Bufo 6x TO 27C 6C .1% TO 20% 0.69% Bufo 27c TO 1M 30C .1% TO20% 0.69% Calc Carb 6x TO 27C 6C .1% TO 20% 1.15% Calc Carb 27c TO 1M30C .1% TO 20% 1.15% Calc Phos 6x TO 27C 6C .1% TO 20% 1.15% Calc Phos27c TO 1M 30C .1% TO 20% 1.15% Calc Fluor 6x TO 27C 6C .1% TO 20% 0.69%Calc Fluor 27c TO 1M 30C .1% TO 20% 0.69% Calendula 6x TO 1M 6C .1% TO20% 0.69% Carbo Veg 6x TO 27C 6C .1% TO 20% 2.29% Carbo Veg 27c TO 1M30C .1% TO 20% 2.29% Chamomilla 6x TO 27C 6C .1% TO 20% 0.69% Chamomilla27c TO 1M 30C .1% TO 20% 0.69% Conium 6x TO 27C 6C .1% TO 20% 0.69%Conium 27c TO 1M 30C .1% TO 20% 0.69% Echinaccea 6C TO 1M 6C .1% TO 20%0.69% Angustifolia Echinacea 6C TO 1M 6C .1% TO 20% 0.69% purpureaHammamelis 6x TO 1M 30c .1% TO 20% 0.69% Hepar Sulph 30C TO 200C 200c.1% TO 20% 2.29% Hepar Sulph 201C TO 9997C 1M .1% TO 20% 2.29% HeparSulph 9999C TO 50M 10M .1% TO 20% 2.29% Hypericum 6x TO 27C 6C .1% TO20% 0.69% Hypericum 27c TO 1M 30C .1% TO 20% 0.69% Iodium 6x TO 27C 6C.1% TO 20% 0.69% Iodium 27c TO 1M 30C .1% TO 20% 0.69% Ipecac 6x TO 27C6C .1% TO 20% 0.69% Ipecac 27c TO 1M 30C .1% TO 20% 0.69% Kali Iod 6x TO1M 6C .1% TO 20% 0.69% Lac Caninum 6x TO 1M 30c .1% TO 20% 2.29% LacBovinum 6x TO 1M 30c .1% TO 20% 2.29% Lachesis 6x to 12c/24x 6c .1% TO20% 1.15% Lachesis 12c TO 197c 30c .1% TO 20% 1.15% Lachesis 198c TO 10M200c .1% TO 20% 1.15% Ledum 6x TO 27C 6C .1% TO 20% 0.69% Ledum 27c TO1M 30C .1% TO 20% 0.69% Lycopodium 6x TO 27C 6C .1% TO 20% 0.69%Lycopodium 27c TO 1M 30C .1% TO 20% 0.69% Merc Sol 30C TO 200C 200c .1%TO 20% 1.15% Merc Sol 201C TO 9997C 1M .1% TO 20% 1.15% Merc Sol 9999CTO 50M 10M .1% TO 20% 1.15% Nux Vomica 6x TO 27C 6C .1% TO 20% 0.69% NuxVomica 27c TO 1M 30C .1% TO 20% 0.69% Phosphorus 6x TO 1M 30c .1% TO 20%1.15% Phytolacca 6x to 12c/24x 6c .1% TO 20% 2.29% decandra Phytolacca12c TO 197c 30c .1% TO 20% 2.29% decandra Phytolacca 198c TO 10M 200c.1% TO 20% 2.29% decandra Pulsatilla 6x TO 1M 30c .1% TO 20% 1.15%Pyrogen 30C TO 10M 1M .1% TO 20% 1.15% Rhus 6x to 12c/24x 6c .1% TO 20%0.69% toxicodendron Rhus 12c TO 197c 30c .1% TO 20% 0.69% toxicodendronRhus 198c TO 996c 200c .1% TO 20% 0.69% toxicodendron Rhus 997C TO 9997C1M .1% TO 20% 0.69% toxicodendron Ruta Grav 6x to 12c/24x 6c .1% TO 20%0.69% Ruta Grav 12c TO 197c 30c .1% TO 20% 0.69% Ruta Grav 198c TO 10M200c .1% TO 20% 0.69% Sabal 6x TO 27C 6C .1% TO 20% 0.69% Sabal 27c TO1M 30C .1% TO 20% 0.69% Sepia 6x TO 27C 6C .1% TO 20% 0.69% Sepia 27c TO1M 30C .1% TO 20% 0.69% Silica 6c TO 100c 30c .1% TO 20% 2.29% Silica101c TO 997C 200c .1% TO 20% 2.29% Silica 998C TO 9997C 1M .1% TO 20%2.29% Stellaria Media 6x TO 1M 30c .1% TO 20% 0.69% Suphur 6x TO 1M 30c.1% TO 20% 2.29% Symphytum 6x TO 1M 30c .1% TO 20% 0.69% Urtica 6x TO 1M30c .1% TO 20% 0.69% Zincum Met 4x TO 12C 4c .1% TO 20% 0.69% Zincum Met6x TO 1M 30c .1% TO 20% 0.69% 100.00%

The following optional nosodes may also be added, at a preferred potencyof 30 C to 1M and a 1:1 ratio of each ingredient: Tuberculinum Bovinum,Tuberculinium Aviaire, Staphylococcus Aureus, Strepococcus, StrepococcusMix, Corynebacterium, E. Coli (ColibacillinuM), Bacillinum andMedorrhinum at a preferred potency of 30 C. E. Coli was added at apreferred potency of 200 C.

The following homeopathic complexes were used in Examples 11 to 20.

Vet Cream

This treatment essentially comprises, Core A and Core B with graphites,sulphur and thuja (the optional Core B ingredients).

Each homeopathic ingredient was combined in approximate equalproportions based on the volume to of the total homeopathic complex andadministered as a cream with a base comprising approximately 25%Lanolin, approximately 50% approximately Petroleum with 25% Mineral oil.

[Short Range for Preferred Remedy form] Topical Use Potency HeparSulphuris [Hep-s] Range 2x-12x/6c 3x Lachesis [Lach] Range 8x-12x/6c 8xMercurius Solubilis [Merc-s] Range 6x-12x/6c 6x Silica [Sil] Range2x-12x/6c 3x Aconitum Napellus [Acon] Range 2x-12x/6c 3x Arnica Montana[Arn] Range MT-12x/6c 3x Arsenicum Iod [Ars-i] Range 6x-12x/6c 6xBelladonna [Bell] Range 2x-12x/6c 3x Bellis Perenis [Bell-p] RangeMT-12x/6c 3x Bryonia Alba [Bry], Range MT-12x/6c 3x Calenula Offcinalis[Calen] Range MT-12x/6c 3x Chamomilla Matricaria [Cham] Range MT-12x/6c3x Echinacia augustifolia [Echi-a] Range MT-12x/6c 3x Echinacia Purpurea[Echi-p] Range MT-12x/6c 3x Graphites naturalis [Graph] Range 8x-12x/6c8x Hamamellis Virginiana [Ham] Range MT-12x/6c 3x Hypericum Perforatum[Hyper] Range MT-12x/6c 3x Ledum [Led] Range MT-12x/6c 3x Millefolium[Mill] Range MT-12x/6c 3x Phytolacca [Phyt] Range 6x-12x/6c 6x RhusToxicodendron [Rhus-t] Range MT-12x/6c 3x Ruta Graveolans [Ruta] RangeMT-12x/6c 3x Stellaria Media [Stel] Range MT-12x/6c 3x Sulphur [Sulph]Range MT-12x/6c 4x Symphytum [Symph] Range MT-12x/6c 3x ThujaOccidentalis [Thuja] Range MT-12x/6c 3xMastitis Treatment

This treatment essentially comprises, Core A and Core B with optionalingredients thuja, sulphur and graphites and additional ingredientsUrtica, Gunpowder and Conium. The addition of Gunpowder is optional anddepends on Regulatory Rules.

Each homeopathic ingredient was combined in approximate equalproportions based on the volume to of the total homeopathic complex andadministered as a cream with a base comprising approximately 25%Lanolin, approximately 50% approximately Petroleum with 25% Mineral oil.

Preferred Effective Final Potency Range Preferred dilution in Remedy forTopical Use Potency Cream Hepar Sulphuris 2x-12x/6c 3x 4x Lachesis8x-12x/6c 8x 9x Mercurius Solubilis 6x-1x/6c 6x 7x Silica[Sil] 2x-1x/6c3x 4x Aconitum Napellus 2x-12x/6c 3x 4x Arnica Montana MT-12x/6c 3x 4xArsenicum Iod 6x-12x/6c 6x 7x Belladonna 2x-12x/6c 3x 4x Bellis PerenisMT-12x/6c 3x 4x Bryonia Alb MT-12x/6c 3x 4x Calenula OffcinalisMT-12x/6c 3x 4x Chamomilla Matricaria MT-12x/6c 3x 4x Conium maculatumMT-12x/6c 8x 9x Echinacia augstofolia MT-12x/6c 3x 4x Echinacia Purpurea8x-12x/6c 3x 4x Graphites MT-12x/6c 8x 9x Gunpowder MT-12x/6c 3x 4xHamamellis Virginia MT-12x/6c 3x 4x Hypericum Perforatum MT-12x/6c 3x 4xLedum 6x-12x/6c 3x 4x Millefolium MT-12x/6c 3x 4x Phytolacca decandra6x-12x/6c 6x 7x Ruta Graveolans MT-12x/6c 3x 4x Rhus ToxicodendronMT-12x/6c 3x 4x Stellaria Media MT-12x/6c 3x 4x Sulphur MT-12x/6c 3x 4xSymphytum MT-12x/6c 3x 4x Thuja Occidentalis MT-12x/6c 3x 4x UrticaUrens MT-200c 30c 30cTrauma/First Aid treatment

Each homeopathic ingredient below was combined in approximate equalproportions based on the volume to of the total homeopathic complex andadministered as a liquid in alcohol and water, for example 20% ethylalcohol and 80% purified water.

Preferred Effective Final Potency Range Preferred dilution in Remedy forTopical Use Potency Cream Hepar Sulphuris 2x-12x/6c 3x 3x Lachesis8x-12x/6c 8x 9x Mercurius Solubilis 6x-1x/6c 6x 7x Silica[Sil] 2x-1x/6c3x 4x Aconitum Napellus 2x-12x/6c 3x 4x Arnica Montana MT-12x/6c 3x 4xArsenicum Iod 6x-12x/6c 6x 7x Belladonna 2x-12x/6c 3x 4x Bellis PerenisMT-12x/6c 3x 4x Bryonia Alb MT-12x/6c 3x 4x Calenula OffcinalisMT-12x/6c 3x 4x Chamomilla Matricaria MT-12x/6c 3x 4x Conium maculatumMT-12x/6c 8x 9x Echinacia augstofolia MT-12x/6c 3x 4x Echinacia Purpurea8x-12x/6c 3x 4x Graphites MT-12x/6c 8x 9x Gunpowder MT-12x/6c 3x 4xHamamellis Virginia MT-12x/6c 3x 4x Hypericum Perforatum MT-12x/6c 3x 4xLedum 6x-12x/6c 3x 4x Millefolium MT-12x/6c 3x 4x Phytolacca decandra6x-12x/6c 6x 7x Ruta Graveolans MT-12x/6c 3x 4x Rhus ToxicodendronMT-12x/6c 3x 4x Stellaria Media MT-12x/6c 3x 4x Sulphur MT-12x/6c 3x 4xSymphytum MT-12x/6c 3x 4x Thuja Occidentalis MT-12x/6c 3x 4x UrticaUrens MT-200C 30c 30c

Example 1

Subject

Springer Spaniel Female neutered, age 5 years old on Day 0.

Condition/Symptoms of Subject

-   -   The patient presented with non-healing wound of what appeared to        be a MRSA-type infection resulting from minor surgical wound as        a result of elective surgery in the area of the stopper pad. The        owner described the original wound as having been completely        closed after surgery.    -   The patient had an ulcerative skin lesion which had started        after minor surgery and had gradually extended.    -   There had been no response to repeatedly changed conventional        antibiotics (Fuciderm®) or the antibiotic impregnated dressings        used    -   After using a number of conventional antibacterial therapeutics        the owner had decided to try an alternative approach.        Treatment

On Day 0 the patient was taken off all oral conventional medication. Acream consisting of Core A and Core B with the addition Fucidin wasapplied by mixing a tube of Topical Ophthalmic Antibiotic FUCITHALMIC®Viscous Eye Drops (1% fusidic acid). The Cream was applied to theaffected area generously and the area bandaged up with cotton wool andan elastic self adhesive bandage and covered with an elastic adhesivebandage. Four days later, a very substantial improvement in thepatient's condition was observed. Treatment with just a cream consistingof core A and core B was then repeated without the addition of theFucidin. The patient was next seen in 5 months later and the treatmenthad been successful.

Conclusion

The dramatic and unexpected response in this subject confirms what hasbeen seen in many other patients that the homeopathic complex of theinvention work. There are no reported side effects, toxicity,administration was easy and the effectiveness in this species wasdramatic and successful.

The homeopathic complex of the invention comprising Core A and Core Bwork when co-administered with conventional therapeutics, when theconventional therapeutic (antibiotic) did not work on its own. It showsthe synergy with conventional therapy with no negative interaction

This example also indicates that the homeopathic complex of theinvention is capable of saving lives as in the case of this subjectwhere it was non-responsive before treatment, with the potential ofhaving a limb amputated if the condition had continued to progress as ithad been, not only did it save the subject from an amputation withpossible similar consequences, but it restored the limb to fullnormality completely healing the ulcers

Example 2

Subject

Feline male neutered of indeterminate age

Conditions/Symptoms of Subject

The subject originally presented as a post road traffic accidentpatient, with multiple traumatic skin injuries and multiple fractures ofthe left femur the latter were repaired by open reduction andintramedullary pining. The fracture site had to be partially re-brokenas there was already cartilaginous callus repair with very mal-alignedbone fragments.

The subject was post shock. It was already in the healing phase ofinjury, but the wounds were still open and fresh. The bone fractureswere attempting to heal out of alignment. The subject was initiallyunable to walk on the hind legs despite having one un-fractured leg. Themusculature bones and wounds were all painful. The wounds were due tograzing probably from contact with a road surface and so friction burnsas well as wounds, bruising and fractures were present.

Treatment

The fractures were treated by open reduction. Immediately post surgerythe patient was administered a 0.21 ml liquid dropper dose of a complexof Cores A, B and C combined in an excipient of 20% ethyl alcohol and80% purified water. This was given on a first aid basis to aid recoveryand promote rapid healing. Subsequently, a cream comprising Core A and Bfor topical application in a base carrier of 25% Lanolin and 50% whitepetroleum at 2 oz/lb and 25% mineral oil with the homeopathiccombination added at 3.33% Vol/Vol (3.33 ml/100 ml) w/w (3.33 g/100 g)was applied topically to all wounds and known bruised regions includingthe surgical wound particularly over the fracture site. Antibiotic coverwas provided by Crystapen into the surgical wound and parentalAmoxycillin and Clavulanic Acid (Synulox Pfizer), but would not explainthe rapidity of recovery other than the absence of infection.

Result

FIG. 1a shows the subject of Example 2 pre-treatment and FIG. 1b showsthe subject of Example 2 after a 24 hour of treatment.

The results were dramatic with the patient walking to obtain food within48 hours of the surgery. Not only that but as pictures FIG. 1a and FIG.1b show the rate at which healing progressed in this patient with thegap between photographs of the same wound being of the order of 24hours. All wounds had completely resolved in a 10 day period.

Conclusion

This case shows the unexpected rapidity of wound, fracture and injuryresolution brought about by the use of the Cream with Core A and Bcombined topically and the oral administration of just a singleunrepeated dose of Core A, B and C in a liquid dose form.

It once again shows the synergy with conventional therapy with nonegative interaction. Once again there were no reported side effects,toxicity, administration was easy and the effectiveness in a differentspecies to Example 1 was just as dramatic and successful

Example 3(A)

Subject

“Sambo” Equine Gelding 14-16 years old

Conditions/Symptoms of Subject

-   -   Subjects, “Sambo” Equine Gelding 14-16 years old and a piebald        mare, presented with acute severe photo-dermatitis due to sun        over-exposure.    -   All the un-pigmented skin on the nose was suffering from severe        solar radiation burns (FIG. 2a )    -   The skin on the nose was sunburnt, oozing, scabby, cracked, and        painful to movement and touch. There were also patches of        sloughing.        Treatment

A cream comprising Core A and B for topical application in a basecarrier of 25% Lanolin and 50% White Petroleum at 2 oz/lb and 25%mineral oil with the homeopathic combination added at 3.33% (3.33 ml/100ml) was applied topically on a twice daily basis for 5 days to theaffected areas of the subject and then once daily due to the rapidity ofimprovement.

Results

FIG. 2a was taken on day one with FIG. 2b taken 11 days later. Thehomeopathic complex used promoted rapid healing and also conferred someform of resistance to further sunburn or sun sensitivity

This protocol has been repeated with other horses with exactly similarresults. In one patient so severe was the reaction that the glands onthe neck swelled up in acute response. The affected area was so sorecream could only be applied around the affected area. However, a similarresponse was achieved.

Conclusion

Previous cases of equine photo-dermatitis had taken between 3 months inmild cases, to 6 months in similarly severe cases to recover and then inmany cases residual scarring was present. This case shows the unexpectedrapidity of burn resolution brought about by the use of a topical creamwith Core A and B.

Example 3(b)

Subject

Herd of male and female pigs less than 1 year of age

Conditions/Symptoms of Subject

Subjects were presented with acute severe photo-dermatitis after beingleft out on new pasture during a period of unbroken sunshine. Thesubjects presented much as a case of bad human sunburn would (FIG. 3a )with the whole patient having a bright red burning hot inflamed tenderskin with crusting of the skin at the worst affected areas where therewas deep cracking due to third degree burning. There were areas ofpeeling and scabbing of the affected skin.

Treatment

Due to success with previous cases in a range of other species atreatment with Core A and Core B combined was used. However, due to thenumber of animals a novel delivery method was required. Aloe VeraVeterinary Spray (Forever Living Products) was used as a carrier forCore A and Core B. Once daily spraying of the carrier with Core A andCore B was decided upon with a second spray when possible at feedingtime.

Result

A complete and total resolution of all the symptoms of severe sunburnleaving normal healed skin was achieved in 10 days and this change isshown in FIG. 3b . The skin is normal pink and healthy with no signsthat would normally be expected with this degree of sunburn having beenpresent 10 days earlier. This similar to Example 3a the improvement andhealing was achieved in a very short time period.

Conclusion

This case shows yet again the unexpected rapidity of burn resolutionbrought about by the use of the Cream with Core and Core B combinedtopically. In addition, it demonstrates both the healing properties ofthe invention and the anti-sepsis properties of the Cores (none of theburns in the group became infected despite the muck, dirt and flies thatwere present). Additionally, the homeopathic complex minimized scarring.Furthermore, the homeopathic complex may be used with groups, herd,flocks etc.

Example 4

Subject

Cavalier King Charles Female—not neutered age 3¼ years old.

Conditions/Symptoms of Subject

Patient presented with acute mastitis. Initial examination showed thepatient to have a temperature in excess of 104° F./40° C. The mammaryglands were hard swollen and in danger of gangrene on assessment. Thepatient was treated with a combined homeopathic and conventionaltherapy.

Treatment

As the condition was acute severe and life threatening, it was decidedto treat with a combination of homeopathic and conventional therapy.

An initial injection of Synulox® (Amoxycillin Trihyd, Clavulanic Acid)at a dose of 1 ml SC and Clamoxyl LA® (Amoxycillin Trihyd) at a dose of2 ml SC and an oral dose of 15 drops of Cores A, B and C with nosodes atdose of 0.07 ml/drop which was approximately 1 ml liquid dropper dose ofcomplex of Cores A, B and C combined in an excipient of 20% ethylalcohol and 80% purified water to act as an anti-infective wasadministered as a single initial dose. Topical application of a creamcomprising Core A and B for topical application in a base carrier of 25%Lanolin and 50% white Petroleum at 2 oz/lb and 25% Mineral oil with thehomeopathic combination added at 3.33% (3.33 ml/100 ml) was also carriedout. The patient was checked the following day and the mammary glands asevidenced in the picture below had virtually returned to normal. Theowner was told to complete the antibiotic course to prevent anyresistance developing.

Results and Conclusion

The owner reported that by the time the dog got home some 15 minutesafter being given the Cores A, B and C orally as a liquid preparationand having topically applied a cream with Cores A and B the subject hadalready started to improve.

FIG. 4 shows the subject within 24 hours of the start of treatment. Thepatient was checked the following day and the mammary glands hadvirtually returned to normal within a 24 hour period. The owner was toldto complete the antibiotic course to prevent any resistance developing.

Conclusion

This example demonstrates the synergy of the homeopathic complex of theinvention and correctly chosen conventional pharmacotherapy, anantibiotic in this case. It demonstrates the speed of action of thisinvention as some 15 minutes after initiation of therapy there had beenan improvement and within 24 hours there appeared to be almost completeresolution of the mastitis, which was severe and septic in nature. Itdemonstrates that this medication is capable of speeding the resolutionof a very severe case of acute sepsis in conjunction with conventionaltherapy.

Example 5

Subject

Canine Collie Cross Male 1 Year old

Conditions/Symptoms of Subject

-   -   Subject presented with several skin reaction (around nose area)        to hogweed or other related plants (FIG. 5 (a) before (b)        after).    -   The skin had vesicles which were intensely itchy and were oozing        serum as a result of intense puritus.        Treatment

Twice daily topical treatment with cores A and B and oral treatment withmodulator Rannunculus Bulbosa, Sol 30c from core D.

Core A and B were administered as a cream in a buffered cream basecarrier of Purified water BP, Soft White Paraffin BP, Dehydag Wax,Liquid Paraffin BP, DiSodium Hydrogen Phosphate BP Citric Acid BP andChlorocresol BP for Core D modulators added at 3.33% and combined and50% White Petroleum at 2 oz/lb and 25% Mineral oil with the homeopathiccombination added at 3.33% (3.33 ml/100 ml).

Rhus Tox and Urtica Urens 6c were also administered with Core A and CoreB.

Result

Condition disappeared after homeopathic complex administration

Conclusion

This example demonstrates the antipuritic and anti-inflammatory as wellas the wound resolution capabilities of the homeopathic complex. Bothplant chemical burns and auto-immune conditions are generally verydifficult to resolve even over a prolonged period often leaving severescarring or a constantly recurrent condition. The resolution of thiscase alone was unexpected without having a protracted treatment periodwith considerable scaring.

This example also demonstrates the speed, efficacy, safety (as dogscontinually lick off the cream in this location) and ease of use wherethe condition was painful and puritic and yet was alleviated onadministration of the cream.

Example 6: Wound Healing Case Study—Wound Closure of a ChronicallyInfected Non Healing Wound

Subject

Bichon male neutered 6 years old.

Conditions/Symptoms of Subject

The subject presented with severe damage to tissues of the leg wherethere were areas of necrotic tissue that sloughed leaving even moreexposed areas. The patient presented with a suspected hairline fractureof a digit. The leg was severely wounded and was bandaged.

The patient was already on antibiotic therapy and there was antibioticdressing on the wounds. The owner sought a second opinion on the basisthat the wound smelled strongly offensive, the patient was much moretender and lame on the affected leg. FIG. 6a gives a very accurate ideaof the condition the leg was in when the dressing was removed initially,although the picture was taken after ten days of treatment following theinitial second opinion consultation

Treatment

Initial treatment was with antibitiotics Synulox® 250 mg composition(200 mg amoxicillin and 50 mg clavulanic acid) was given orally at adose of ½ tablet twice daily for 7 days along with Metronidazole 200 mg½ tablet twice daily for 7 days. The wound was left open. At this pointdue to lack of progress the antibiotic was changed to Lincocin (Antirobe50 mg) 1 tablet twice daily. Calendula 6c was given orally three timesdaily to try promote healing. Although the wound no longer smelled, itshealing had failed to progress at all.

It was decided at this point to abandon systemic antibiotic therapy totreat the wound. The patient was anaesthetised using ACP2 mg/ml as apremed 0.05 ml IM, Thiopentone 2.5% IV as a knockdown anaesthetic andmaintained on Isoflourane. A swab was taken for culture at this pointdespite antibiotic therapy, as it was hoped that it might give someindication of a suitable treatment. The area around the wound wasclipped and tension sutures placed in the wound which failed to providereasonable apposition but did reduce some of the wound size. The woundwas once again washed with Hibiscrub Surgical Wash, followed by povodineIodine surgical scrub and then rinsed with saline and then bathed insterile water with Homeopathic Mother tincture of Calendula (Marigold)at a dilution of 20 drops of mother tincture add to 100 ml of sterilewater. The wound was then allowed to dry fully and a cream comprisingCore A and B for topical application in a base carrier of 25% Lanolinand 50% White Petroleum at 2 oz/lb and 25% Mineral oil with thehomeopathic combination added at 3.33% (3.33 ml/100 ml). The cream wasto be applied to the open wound 2 to 3 times daily. All antibiotictherapy was discontinued. The most open upper part of the wound hadtension sutures placed in it to draw the edges somewhat closer together.This was to be followed by the application of the cream as described asthe wound still remained very open.

Within 10 days as in the previous examples a huge amount of healing hadtaken place with the photograph FIG. 6b showing the change at day 12.Within 30 days the wound was completely healed and only a thin scarremained (FIG. 6c ) and within a year the scar was virtually completelygone and almost the entire area had normal hair re-growth (FIG. 6d )

Result

20 days after the initial injury and just 7 days after startingtreatment the healing results were amazing the odour was completely gonethe skin and wound showed a dramatic healing even in the area where theskin was black and hard it had gone soft and pink.

Three weeks later, the wound is fully closed, clean with hair re-growth.

Conclusion

The homeopathic complex when applied to this wound acted as ananti-infective as antibiotic therapy was terminated when therapy withthe cream comprising Core A and B was initiated in addition to this therate of wound healing and resolution was dramatically accelerated asshown in FIGS. 6(a-d). The end result was an almost total return tonormal of the affected area, a dramatic result by any standards.

This example demonstrates the true extent of action of Core A and B whenused on their own in a cream delivery system to a wound with indolenthealing features as in this case where after over 10 days there was nosign of granulation or healing in the wound yet with the introduction ofthe invention the wound which was large and non healing suddenly startedto show accelerated healing.

It also demonstrated that this invention acts with similar efficacyacross many different types of wound and skin condition a very uniquefeature. It demonstrates the usefulness of the invention with septicwounds and particularly those with antibiotic resistant infections(Multi-resistant Infections) as in this wound a range of antibiotics hadbeen used with no resolution of the wound. The prolonged nature of thetreatment also demonstrated the safety and lack of toxicity or sideeffects of the invention as the owner continued to apply the creamsparingly to the affected area for months till almost any signs ofscarring let alone the wound had resolved. It also shows how welltolerated the invention is in this format—despite how painful, raw andsensitive the area was the owner was able to apply the invention severaltimes a day.

Example 7(A)

Subject

Human 31 year old Lactating female.

Conditions/Symptoms of Subject

-   -   The subject a 31 year old female developed a complaint of sore        swollen painful breasts associated with the breast feeding of        her second child.    -   The symptoms began to appear within 10 days of leaving the        hospital post birthing.    -   The glands were swollen and painful to the touch, the breasts        were engorged with milk and the patient complained that breast        feeding was difficult at best. There had been no previous        history of any mammary gland infection with the pervious child        birth. A diagnosis of post birthing mastitis was given and a        course of antibiotics were prescribed by the treating physician.        After several days the patient still had no relief and began to        seek alternative options.        Treatment

The patient began treatment with oral dosing of the homeopathicmedication complex for mastitis comprising Cores A, B and C (no nosodes)in dropper dose in an excipient of 20% ethyl alcohol and 80% purifiedwater twice daily with the product being sprayed onto the oral mucosa 13days post birthing.

Result

Relief was established within 24 hours and a total elimination ofsymptoms in 48 hours. There has been no re-occurrence of the conditionor symptoms since treatment

Example 7(B)

Subject

Human 30 year old Lactating female.

Conditions/Symptoms of Subject

A 30 year old white female was presented with health concerns that arose4 days after leaving hospital after giving birth to a female child. Thepatient was in hospital for 3 days and the condition did not manifestuntil 4 days post hospital. This was a second child and the patient didnot have a history of mastitis-mammary gland infections.

Symptoms included a high fever, painfully swollen mammary glands withpain extending under left arm. Breasts were extremely painful to thetouch and breast feeding was problematic at best. General movement wasalso guarded due to the inflammation and pain associated with movement.

Treatment

Three sprays, 2 ml, of the liquid homeopathic medication complex formastitis comprising Cores A, B and C (no nosdoes) in dropper dose in anexcipient of 20% ethyl alcohol and 80% purified water was administeredby the subject 3 times daily for 2 days based on the nature of thecondition and the lack of response to antibiotic therapy on its own.

Result

Pain was reduced after 3 hours, inflammation was reduced within 24 hoursand a total resolution was achieved in 48 hours.

Conclusion

The response confirmed that Cores A to C work as an anti-infective andanti-inflammatory in humans. It demonstrates a rapid response in humansto the invention and that the invention is safe and side effect free inhumans.

It shows that the use of Cores A to C internally (this can also bedelivered transdermally, orally, perivaginally or parentrally)demonstrates a consistent response as a potent anti-infective agent.

Example 7(C)

Subject

Human Male 60+ year

Conditions/Symptoms of Subject

Subject was diagnosed with meningioma and had surgery to remove thesame. As follow up radiation therapy was done 5 days a week for 6 weeks.The subject presented with itching and soreness of the skin over thearea of radiotherapy, a known consequence of radiotherapy.

Treatment

The invention was provided in the form of a cream comprising Core A andB for topical application in a base carrier of 25% Lanolin and 50% WhitePetroleum at 2 oz/lb and 25% Mineral oil with the homeopathiccombination added at 3.33% (3.33 ml/100 ml). The cream was to be appliedto when the skin was itchy and sore after radiotherapy on an as neededbasis.

Result

As soon as the patient applied the cream the skin conditions wererelieved. The patient was able to complete the radiotherapy course withsimple easy to apply relief when required

Conclusion

Core A and Core B formulated as a cream works in humans similar toanimals and this is one of a series of similar cases all with similarpositive results. The invention has a rapid and immediate effect. Theinvention is effective in treating burns, burn wounds, itch, sorenessand radiation burns.

Example 8: Wound Healing Case Study—Septic Post Surgical MastectomyWound Healing

Subject

Tabby and White Domestic Short Haired Cat Female Not Neutered estimatedage 6-7 months

Conditions/Symptoms of Subject

The subject presented as a second opinion case where a unilateralmastectomy had been carried out due to gangrenous mastitis. The subjecthad had the surgery a little less than a week previous to being broughtto us, all her kittens had died prior to the mother arriving with usfrom a combination or the initial malnutrition and sepsis from themastitic milk. Thus only the mother was presented and she had continuedto deteriorate during the post surgical period much as had occurred withthe kittens. The subject presented with a fever of T103.5° F. and wasalready on Convenia a 14 day duration antibiotic active ingredientCefovecin a cephalosporin and was failing to improve. The patient was inappetent and a large area of tissue was still on the point of sloughing.The initial presentation was fairly dramatic with a lack of response toconventional medications (FIGS. 7a to 7d ).

Treatment

The subject was given twice daily oral dosing with 5 drops or 0.35 ml ofthe delivery dose was administered by mouth twice daily. The deliverydose comprised of Cores A, B and C with the following Nosodes:Tuberculinum Bovinum, Tuberculinium Aviaire, Staphylococcus Aureus,Strepococcus, Strepococcus Mix, Corynebacterium, E. Coli(ColibacillinuM), E. Coli, Bacillinum and Medorrhinum, in a liquiddropper. Cores A, B and C with Nosodes were combined and added at a rateof 0.07 ml/ml in an excipient in glycerine 30% with purified water toact as an anti-infective. In addition cream comprising Core A and B fortopical application in a base carrier of 25% Lanolin and 50% WhitePetroleum at 2 oz/lb and 25% Mineral oil with the homeopathiccombination added at 3.33% (3.33 ml/100 ml). The cream was to be appliedto the open wound 2 to 3 times daily. All antibiotic therapy wasdiscontinued.

Result

Within 24 hours the non responsive subject had a decrease in it pyrexiafrom T103.5° F. to T102.2° F. and had started eating. The patient hasalso started drinking again, the wound still looked appalling, but had aless putrid odour FIG. 7a and within in 3 days the patient had improveddramatically with the gangrenous area having sloughed and healing hadstarted to rapidly occur in the affected area the cat was now eating,drinking, walking around and purring again.

Within 7 days the entire wound area was dry an all oozing gone due tothe rapid rate of healing the fact that the patient had previously beenunder general anaesthesia for the original surgery and non responsivetreatment Applicants decided to allow the wound to heal by secondintention.

FIG. 7c —ten days after initiating treatment the patients wound hadreduced in surface area sufficiently for some areas of the wound to havestarted to close showing no trace scarring.

FIG. 7d —at the three week stage healing was virtually complete and thepatient sent home. Further reports on the subject is that it continuesto do well and no one would know the problem was ever there

Conclusion

The homeopathic complexes administered are effective in the presence ofresistant infection not susceptible to previously chosen antibioticcover and produce a rapid response with a fast drop in temperatureshowing the invention acting as an anti-pyretic. The invention is safeas there were no side effects seen where the invention was applied bothinternally and externally over a large surface area for a prolongedperiod in a subject. The invention act as a potent anti-infectivecomposition. The invention promotes wound healing even in very largeseptic wounds. The invention can be co-administered with antibiotics.The invention is non-toxic, the subject being a cat continually washedthe cream off its coat for the entire duration of treatment and showedno ill effects. The invention has anti-inflammatory and analgesicproperties as the subject was rapidly able to get up and walk around.The invention is easy to use due to the above the subject allowed easyadministration of the invention to area that were obviously sore. Theinvention can be administered by multiple routes and by multipledelivery methods.

Example 9: Wound Healing Case Study—Treatment of Mastitis and MammaryHypertrophy

Subject

Domestic Short Haired Cat F <2 years

Conditions/Symptoms of Subject

The subject had already received treatment before being brought for asecond opinion. The subject had already been given Convenia, a 14 dayduration antibiotic with active ingredient Cefovecin (a cephalosporin),and had failed to improve over the subsequent treatment period and hadin fact got worse with the mammary glands continuing to increase in sizeand discolouration, the patient had become lethargic and in-appetent,but still continued to eat some food.

The subject presented with massive mammary hypertrophy and a history ofwhat was diagnosed as mastitis. FIG. 8a shows the degree to which themammary glands were enlarge discoloured. FIG. 8b shows the ball that wasplaced between the glands as a reference to show the true size of thegland swelling.

Treatment

The subject was given twice daily oral dosing with 5 drops or 0.35 ml ofthe delivery dose was administered by mouth twice daily. The deliverydose comprised of Cores A, B and C with Nosodes as per Example 8 in aliquid dropper. Cores A, B and C with Nosodes were combined and added ata rate of 0.07 ml/ml in an excipient in glycerine 30% with 70% purifiedwater to act as an anti-infective. In addition cream comprising Core Aand B for topical application in a base carrier of 25% Lanolin and 50%White Petroleum at 2 oz/lb and 25% Mineral oil with the homeopathiccombination added at 3.33% (3.33 ml/100 ml). The cream was to be appliedto the entire mammary are 2 to 3 times daily. All antibiotic therapy wasdiscontinued.

Result

Within 10 days there was complete resolution of the condition the speedand rapidity of which is evidenced when one compares FIG. 8a and FIG. 8b. The glands which were sufficiently large to hold the ball between themand were much larger than the 1.5 cm ball had within 10 days returned toan almost flat in active state. A remarkable change considering thestarting point and the lack of response to previous therapies

Conclusion

Thus, the homeopathic complex of the invention is effective in thepresence of resistant infection not susceptible to previously chosenantibiotic cover and produces a rapid response with a rapid reduction insize of the affected mammary glands on a daily basis.

The invention is safe as there were no side effects seen where theinvention was applied both internally and externally over a largesurface area for a prolonged period in a subject. The invention is nontoxic.

The homeopathic composition of the invention act as an effectanti-infective in cases of mastitis which is both complementary andsynergistic with conventional medication and promotes healing asdemonstrated in this Example.

The invention can be co-administered with antibiotics.

Furthermore, conventional treatments for mastitis and mammaryhypertrophy did not achieve the same effect and the nine day return tonormal of the patient in this example was exceptionally rapid. Theauthors note a case where the hypertrophy had been present for 8-12weeks and after starting after an injection of delvosterone hadcontinued to get larger on a daily basis until Delvosterone 11c wasgiven. In this case the reduction was slower and damage took longer toheal.

Example 10: Homeopathic Therapy Evaluation for Subclinical Mastitis inLactating Holstein Cows

Field trial were carried out using an anti-infective homeopathic complex

Materials

The Mastitis treatment was administered as defined in the Generalmaterials section. Nosodes were not included for the purposes of thistrial.

The homeopathic ingredients were extracted in 95% ethanol (USP, BP, EP)and 10% triple distilled water. The following carrier was used for theresultant homeopathic complex 20% ethanol and 80% purified water.

Objective:

The objective of this study was to evaluate the effect of thehomeopathic treatment above, on somatic cell counts and immune status ofcows.

Introduction:

High somatic cell counts (SCC) in milk are the primary indicator of aninfection in the mammary gland and intramammary infections result inreduced milk production and lower quality of milk. Elevated somatic cellcounts can be the result of a clinical or sub-clinical infection or, insome cases, SCC may be elevated in the absence of a pathogenic organism.Generally, if a cow exhibits clinical mastitis, then this cow is treatedwith an antibiotic, by intramammary infusion or systemically, dependingon the severity of the clinical signs. If a sub-clinical infection isdetermined from a microbial culture of the milk, the cow is monitoredbut not treated until the end of lactation, since treatment of thesecases during lactation is not usually effective. Treatment at dry-offhas been established to be the most effective treatment for asub-clinical mastitis infection. Sub-clinical infections result inreduced milk production that can be a loss of several thousand dollarsper animal per lactation. In addition, elevated SCC results in the lossof quality premiums for producers. Therefore, reducing SCC andsub-clinical infections are beneficial for both animal health andprofitability. Alternative treatments, including homeopathic treatments,have been suggested as effective treatments for sub-clinical mastitis orother health concerns for dairy cows. However, these products have notbeen adequately researched under controlled study conditions and theonly information available is from testimonial reports and studiesconducted by the industry that did not have appropriate controls andhave not been published. It is unknown if the product, Mastoblast, iseffective in reducing SCC and if the product can reduce the incidence ofintramammary sub-clinical infections.

Protocol:

Twenty-four lactating cows from the University of Connecticut diary herdwere selected based on the pattern of somatic cell counts in milk andthe presence of a mastitis pathogen (sub-clinically infected) from theCT Mastitis Laboratory. Animals were then paired by SCC, infectionstatus, age and stage of lactation and randomly assigned to one of thetwo treatments within classes of infection status.

Treatment design was follows:

Treatment A Mastitis treatment 6 cows with positive cultures (ifpossible) 6 cows with negative cultures Treatment B Control treatment 6cows with positive cultures (if possible) 6 cows with negative cultures

Cows were housed separately by treatment group within the Kellogg DairyCentre throughout the study period.

Cows were aseptically cultured at day −3 and day −1 and day 3 to verifythe intramammary infection status and SCC and at least nine cows will beassigned to each treatment. The homeopathic treatment and controltreatment were administered as a spray on the nasal membranes for 10days starting at day 5. Starting at day 2, milk was sampled from theafternoon milking for SCC analysis every three days for two weeks.Thereafter, milk was sampled for SCC once weekly through 8 weeks. Milkwas sampled aseptically for pathogen analysis on a two-week basis up to10 weeks. Daily milk production was recorded. Monthly milk fat andprotein content was determined from DHI testing. Blood, fromveni-puncture and milk samples was collected from each animal at twiceper week to measure differential counts of white blood cells to assessimmune status in the cows. Effect of the treatment on SCC, milkproduction and immune status was analyzed by ANOVA and the GLM procedureof SAS.

Materials and Methodology

The study was 60 days in length. At day 1, foremilk was asepticallycollected from each quarter of all cows and analyzed for mastitispathogens at the University of Connecticut Mastitis Laboratory andbacteriological status of milk samples was determined by diagnosticprocedures recommended by the National Mastitis Council (1987). Milk wasthen sampled from the total milking of each cow on day −1 and analyzedfor SCC (Marshall, 1992) and for the immunoglobulins G₁ (IgG₁) usingELISA quantitation kits (Bethyl Laboratories, Inc; Montgomery, Tex.).These values provided baseline nonspecific estimates of the intramammaryinfection status of each quarter and the immune system status.

On day 1 through day 10, the homeopathic therapy and the placebo wereadministered twice daily before each milking. On days 3, 7, 10, 13, 16,22, 28, 35, 42, 49, and 56 milk was sampled and analyzed for SCC. Ondays 3, 13, 22, 28, 35, 42, 49 and 56 the milk samples were alsoanalyzed for IgG1. In addition, on days 28 and 56, foremilk from eachquarter for all cows was aseptically collected and analyzed for mastitispathogen as described earlier. If a cow developed clinical mastitis, thedata from that cow were removed from the analysis due to markedincreases in SCC and immunoglobulins due to clinical mastitis that maybias the analysis. In this study, the sample size was not large enoughto accurately determine treatment differences for clinical mastitis,because clinical mastitis is usually a low incidence disease.

Results

P Values Treatment Time Treatment time SCC 0.87 0.48 0.46 IgG1 0.0060.0001 0.0001 IgG2 0.52 0.17 0.0002 Infections 0.12 0.63 0.35Significant effects from IgG1, only

These results show significant effects for IgG1 only. The IgG1 is theonly immunoglobulin to show significant change the IgG2 section wasaffected by the cattle not receiving homeopathy developing mastitis andhaving to be removed from the trial. This factor was not part of thetrial results as it was not part of the parameters to be examined, butthe actual incidence of mastitis in the animals not receiving thehomeopathic medication was much higher than those who received thehomeopathic medication. The change in the significant changes in IgG1may have been related to the reduced incidence of mastitis. The lack ofchange in IgG2 may have been related to the masking of this effect bythe intrusion of clinical mastitis into the trial in the non homeopathicgroup—without this there may also have been a change in IgG2. Both IgG'shave been associated with mastitis and conferring protection againstmastitis in cattle (see FIGS. 9a and 9b ).

Conclusion

Applicants found that the actual incidence of mastitis in the animalsnot receiving the homeopathic medication was much higher than those whoreceived the homeopathic medication. Thus, the conclusion is that aneffect in IgG1 was seen while the animals were on homeopathic treatment.

Example 11: Wound Healing Case Study—Accelerated Wound Closure andHealing

Subject

Jack Terrier, male neutered, 10 years old

Conditions/Symptoms of Subject

The patient presented in shock with multiple bite wounds, which wereacutely painful, with difficulty in breathing and the danger of aninjured trachea temporarily ruled out treatment under generalanaesthesia.

Examination of the wounds revealed that the bites had penetrated throughthe skin to cause substantial damage to the underlying muscles at thejunction of the neck and chest between the axillae, around the dorsalaspect of the left foreleg, and over the rib cage on the left side.

Treatment

Initial therapy included clipping the wounded area and washing the skinmargins with Hibiscrub surgical scrub followed by povidone iodine. Theopen wound was then bathed in sterile water with Homeopathic Mothertincture of Calendula (Marigold), at a dilution of 20 drops of mothertincture add to 100 ml of sterile water. The wound was gently dabbed dryand Vet Cream (Core A and Core B in the form of a cream) was liberallyapplied to the entire affected area and the surrounding tissue close tothe wound margin. The owner was instructed to apply the cream to theaffected area 2-3 times daily.

When wound treatment was complete the patient was given a single 15 dropdose of Trauma/First Aide Complex. Antibiotic cover was instigated witha single 0.5 ml intramuscular injection of Synulox RTU (Pfizer AnimalHealth). Maintenance of antibiotic cover was supplied by Synulox 250 mgtablets (Pfizer) at a dose rate of ½ a tablet twice daily for 5 days.

Results

Two days after the initial consultation the tissue around the wounds wasobviously bruised, but dramatically less. The painful breathinginitially apparent on the day of presentation was considerably betterand the fluid from the underlying lacerated muscle layer was drainingfrom the wounds. A decision was taken not to suture the wounds weighingup the benefits of the drainage as well as the absence of sepsis and thedramatic decrease in pain.

Seven days after the initial attack, the wounds were already closingover and there was no evidence of bruising or local skin damage (seeFIGS. 10a to 10c ).

Conclusion

The rapidity of healing is very clear where there is a totaldisappearance of tissue bruising and all surface injuries, other thanthe major wound points, had literally vanished. In the same period thewound holes themselves had produced healing edges and had filled in theopen areas completely. In general with wounds like this one expectssepsis or at the very least a large amount of tissue swelling andbruising that lasts some weeks and that a drain might be required. In apatient with no anti-inflammatory or analgesic treatment (as in thiscase) one would not normally have expected the patient to be fullymobile in two days.

Example 12: Wound Healing Case—Bite Wound Healing

Conditions/Symptoms of Subject

The patient (canine) originally presented with what was thought to be aself inflicted skin condition from scratching, described as hair comingoff with scabby eruptions. However, on further examination this appearedto be like that of a dog that had been savaged and the area around theeye in fact looked like a wound rather than a self inflicted injury.

Treatment

Considering that the initial appearance of the skin resembled that of atraumatic wound, it was decided to treat the presenting signs ratherthan any underlying condition as no underlying cause could bedetermined.

Vet Cream (Core A and Core B in the form of a cream) was administered.Sulphur 9× (Sulphur at a dilution 1:10⁻⁹) homeopathic was also suppliedto be used on a twice daily basis just in case the owners assumption ofa parasite cause such as sarcoptic mange was correct and to provide anon steroid anti-puritic effect. However, this was stopped afterconfirmation from the owner that the wounds were the result of a fight,and administration twice daily of the Vet Cream was continued.

Results

The area below the eye with the open wound had completely disappeared inthe intervening five weeks, with no trace of an open area. No trace ofany wound was visible on the dorsal area.

Example 13: Wound Healing Case Study—Treatment of a Simple Slow HealingWound

Subject

Blonde coated Lurcher, Female Neutered, 14 months old

Conditions/Symptoms of Subject

The patient was presented three weeks after the initial injury with anincised-type wound that although small just would not heal.

Treatment

No antibiotic cover was provided during treatment, nor were anyanti-inflammatories either topical or oral used during the treatment ofthis case. The only treatment used from the initial presentation tofinal cure was Vet Cream (Core A and B in the form of a cream) on atwice daily basis till the wound appeared to be healing and then toapply it once daily.

Within two days of starting the application of Vet Cream the wound hadstarted to heal and the owner reduced application of the cream to oncedaily. Within six days the wound had healed completely.

Example 14: Wound Healing Case Study

Subject

Greyhound Brindle & White Neutered Male 7 years old

Conditions/Symptoms of Subject

The injury was caused by running under a wooden pole and him catchinghis back on a protruding nut. The skin on the back literally peeledback.

Treatment & Results

The wound was repaired under general anaesthesia 0.1 ml Acetylpromazine2 mg/ml IM as premed and Thiopentone 2.5% IV to effect (15 ml used) as aknockdown dose and anaesthesia was maintained with Halothane. There was90 minutes of surgical time excluding the time taken for preparation ofthe wound for surgical repair which included clipping the area andwashing the skin margins with Hibiscrub surgical scrub followed bypovodine iodine. The open wound was then bathed in sterile water withHomeopathic Mother tincture of Calendula (Marigold) at a dilution of 20drops of mother tincture add to 100 ml of sterile water. The wound wasthen sutured using mattress sutures to appose the edges, as the patienthad a history of tearing wounds open. The large areas which wereunattached to the underlying facial tissue were tacked down using singleinterrupted sutures to enhance the chances of reattachment. A decisionwas taken not to insert a drain into the wound initially. When woundrepair was complete the patient was given a single 15 drop dose ofTrauma/First Aide. Antibiotic cover was instigated with a single 2.5 mlintramuscular injection of Synulox RTU (Pfizer). Maintenance ofantibiotic cover was supplied by Synulox 250 mg tablets (Pfizer) ×15 ata dose rate of 1½ tablets twice daily.

Vet Cream (standard combination Core A and B in the form of a cream) wasliberally applied to the entire affected area and the surrounding tissueclose to the wound margin. The owner was instructed to apply the creamto the affected area 2-3 times daily. The patient had an uneventfulrecovery despite the degree of degloving and the extent of the wound andthe previous history of the patient's wounds breaking down. Theantibiotic cover was not extended beyond the initial 5 days and noanalgesic or anti-inflammatory other than the Vet Cream was used. Therewas no wound breakdown nor was there any need for a drain in the wounddespite its extensive size, which is a common event with injuries suchas this.

Example 15: Severe Bruising (Case with Two Fractured Legs)

Subject

Labrador cross Retriever male 1 year old

Condition

Both hind legs were fractured as a result of a car impact. The damagedone to the car indicated that the patient was lucky to be alive.

The endotracheal tube used to intubate the patient during anaesthesiawas covered in blood indicating severe damage not just to the legs butalso to the lungs with some degree of pneumothorax.

Treatment

The subject received three doses of Trauma/First Aid in the first twentyfour hours, and then once daily for three days. The entire bruised areahad a formulation of Vet Cream (Core A and Core B) applied on a dailybasis for the first five days. The subject was also placed onClindamycin 22 mg/Kg twice daily for the initial 5 days but noanti-inflammatory or analgesic drugs were required.

By the end of the 5 day treatment period the subject was consideredrecovered to the point of being able to support weight on the legs. Thesubject also removed his sutures after less than twenty four hoursfollowing presentation, but as the wound remained closed this healeduneventfully despite the severe bruising of the immediate tissue. Thiscase indicates that the Trauma/First Aid treatment promoted rapidhealing, promoted extremely rapid resolution of the wounds, bruising andfractures. What is unexpected for an injury such as this is the speed ofrecovery and the disappearance of all bruising in less than 6 days suchthat the subject was able to put weight on both back legs.

Example 16: Use of Anti-Infective Core A for Paw that was Golf BallSized Due to Bite Abscess

Subject

Cat 3 years

Condition:

Injured paw with bite abscess

Treatment

Core A at a low C potency was administered to the subject in liquid formfor oral mucosal administration.

Concentration Remedy Vol/Vol % Potency Hepar Sulphuris 25% 6c Lachesis25% 6c Mercurius Solubilis 25% 6c Silica 25% 6c

The above homeopathic complex was supplied in a base of 20% alcohol and80% water, as well as second base of 30% glycerine and 70% purifiedwater. Both were administered to the same patient to assess if anydifference in efficacy could be noted and both worked equally well.

The paw on Day 1 is shown in FIGS. 11a and 11 b.

At day 10 the subject was putting equal weight on both feet.

Example 17: Use of Anti-Infective Core A

Subject & Condition

Canine presented with anal gland abscess. FIG. 12a shows, on Day 1, anAnal Gland Abscess (arrowed) in the Left anal gland where the whole Lside of the peri-anal area was extremely swollen and a sinus wasdischarging pus

Treatment

The pus was cleaned away from the sinus and the midline and showed howmuch the area was swollen. The patient was given Core A only in highpotency, above 200c, for oral administration.

Concentration Remedy Vol/Vol % Potency Hepar Sulphuris 25% 200c Lachesis25% 200c Mercurius Solubilis 25% 200c Silica 25% 200c

The above homeopathic complex was supplied in a base of 20% alcohol and80% water, as well as second base of 30% glycerine and 70% purifiedwater. Both were administered to the same patient to assess if anydifference in efficacy could be noted and both worked equally well.

No other form of medication (including antibiotics) was used. On Day 3,the wound was no longer discharging pus and the swelling in the area wasvastly reduced.

As the abscess had cleared, a Vet Cream (comprising Core A and Core B inthe form of a cream) formulation was applied to the affected area toenhance the healing. FIG. 12b shows the anal gland abscess on Day 7which had completely cleared and the sinus was completely closed. 4 daysafter administration of Vet Cream complete resolution of the wound hadoccurred. Both the speed of abscess and wound resolution in this casewere remarkable.

Example 18

Subject & Condition

A surface tissue injury to the left thumb of a human subject caused bythe trapping of the thumb between a power hose and a granite stone.

Treatment

The injury was treated with Vet Cream (Core A and Core B in a cream)which was liberally applied to the entire affected area and the tissueimmediately surrounding the wound margin.

Within 24 hours following treatment with Vet Cream Formulation the leftthumb showed a significant degree of healing allowing the subject tocontinue to work manually with dirt and water and no protective coveringon the wound. Despite regular immersion in water during the subject'swork day, the wound healed further (data not shown).

Two days from the initial injury and after a full day's work again,which includes manual labour and immersion in water while beingunprotected, it was observed that further rapid healing had occurreddespite it being on a point of flexion where healing is usually muchslower.

Less than one month after the original injury (Day 27), the wound wasentirely healed despite continuous manual work and daily immersion inwater.

This example demonstrates how effective the Vet Cream Formulation is intreating human injuries as well as animals under even more rigorousconditions than would normally be expected, as the wound was on aflexing region and was immersed daily in water and subjected to hardmanual work.

Example 19

Subject & Condition

The subject presented with severe bruising and pain around the anklejoint and foot immediately after a hamstring injury.

Treatment

Trauma/First Aid treatment was taken three times in the 8 hours postinjury and Vet Cream (Core A and Core B in a cream formulation) wasapplied to the area of the injury and the area of subsequent bruising.

The cream was applied twice daily for 3 days in morning and evening andthen daily for 3 days. After that the cream was applied approximatelyevery 2^(nd) day twice daily.

A similar injury had occurred to the opposite leg a few years previouslywhich took in excess of 6 weeks to recover and walk without a legstocking to keep down the oedema, swelling, and bruising. In this casewhere the subject was treated with the Trauma/First Aid treatment andVet Cream Formulae, the subject was walking reasonably comfortably bythe 7^(th) day post injury, and by the 15^(th) day post injury thesubject was back cycling despite the fact that the initial assessment ofthe injury was much worse.

Example 20: Wound Healing Case Study—Treatment of a Septic CompoundFracture and Accompanying Wound

Subject

Black and White Domestic Shorthaired Cat MN less than 1 year old

Conditions/Symptoms of Subject

The subject had been presented to two different veterinary surgeries.The first veterinary surgeon had given Betamox LA (suspension containing150 mg/ml amoxycillin as Amoxycillin Trihydrate BP) at the correct doseof 15 mg per kg bodyweight and was given further antibiotic coverprovided by a single long acting injection of Convenia at the correctdose of 8 mg cefovecin/kg body weight (1 ml/10 kg body weight of) by asecond veterinarian surgeon. About 24 hours after returning to hiscarers the wound started to discharge pus again, but it was decided towait as the patient was on Convenia and improvement might still occur.However, the wound continued to discharge purulent material.

Treatment

On initial presentation the affected region produced a profuse purulentdischarge, which was foetid in odour, when pressed and the whole areafelt like it might slough due to the purulent undermining. The femurcould be felt under the skin and had obviously penetrated through thewound site, before slipping back in giving a compound fracture. Thewound was flushed with Calendula & Echinacea Mother tincture diluted ata rate of 20 drops (1 ml) per 100 ml of Sterile water and 1 ml ofAntirobe (clindamycin hydrochloride) 100 mg/ml. The subject was alsoinjected with Antirobe (clindamycin hydrochloride) 100 mg/ml at a doserate of 22 mg/Kg. A request was put in to the original veterinarypractice for a full case history and x-rays, which are shown in FIGS.13c and 13 d.

The condition of the leg following a 2^(nd) flushing with CalendulaEchinacea and Clindamycin solution was improved, with the dischargebeing less purulent. However, some small clots of pus and necroticdebris could still be seen in the serous discharge that still cameprofusely from the wound.

A decision to surgically repair the leg, if possible, was taken. FIG.13f shows that some of the muscle shearing caused by the distal portionof the femur which perforated the skin had become septic.

Pre-surgery the subject was put on a daily injection of Antirobe(clindamycin hydrochloride) 100 mg/ml at a dose rate of 22 mg/Kg. Thesubject was anaesthetised using xylazine and ketamine as knock downagents and maintained in isoflourane. A decision to try and repair theleg was taken at this point and surgical intervention was under taken toattempt a full reduction of the fracture site. When the lower portion ofthe femur was exteriorised both veterinarians involved in the surgerywere absolutely taken aback by the absolutely foetid odour of the distalfemur, particularly the bone marrow. A decision was taken remove as muchbone marrow as possible and then to wash out the cavity with ahomeopathic complex consisting of Echinacea, Hepar Sulph, Calendula,Symphytum and Gunpowder in various potencies, chosen on the basis of thefoetid odour and the osteomyelitis. 500 l of Clindamycin 100 mg/ml wasalso introduced into the cavity. An intramedullary pin of a size smallerthan would normally be used was introduced into the upper fragment ofthe femur and then into the lower portion of the femur resulting in acomplete reduction of the fracture. Crystapen as a white soluble drysterile powder, containing 95.7% w/w Sodium Benzylpenicillin BP, forreconstitution (with Water for Injection Ph. Eur), in bottles containing5 mega-units (3 g) at a dose of rate of 10 mg/Kg and Antirobe(clindamycin hydrochloride) 100 mg/ml at a dose rate of 22 mg/Kg. wereintroduced directly around the fracture site. The wound was then closedwith simple interrupted cat gut sutures for the internal layers and theskin wound was sutured using polyamide sutures.

FIG. 13a and FIG. 13c show the post surgical wound site with Vet Creamapplied and it shows the sinus tract to the infected bone. Immediatelypost surgery 10 drops of Trauma/First Aid treatment was given.

Post surgical care involved cage rest for 26 days. Initially twice dailyapplications of Vet Cream were done, a 10 day course of Clindamycin 100mg/ml at a dose rate of 22 mg/Kg IM, a 5 day course of Silica 200chomeopathic in liquid Solution was administered at a dose rate of 5drops twice daily. Subsequent to stopping the treatment, the subject wasstarted on Calc Phos homeopathies in high potency daily for 3 days toimprove bone healing and Symphytum in low potency was administered twicedaily at a different time of day for 10 days. Both were administeredaway from food.

Twenty four hours after surgery the patient's wound was already healingwell and the sinus had actually closed. Probiotics and Prebiotics weregiven for the first 10 days and neither anti-inflammatories nor wereanalgesics administered. The subject was attempting to walk from thenext day, which is a common result where Trauma/First Aid has been usedwith Vet Cream.

Just two days after surgery, the subject was standing unsupported on theinjured leg and the large open wound is already starting to heal. Also,it was noticed that with Vet Cream treatment, hair re-growth is enhancedas well as wound repair.

As the subject developed a liking to the taste of the Vet Cream, it wasnecessary to simply apply the Vet Cream just as the subject was beingfed. In addition, the subject was still being given Clindamycin daily,probiotics, Vet Cream a course of Silica 200c at this point.

FIG. 13b demonstrates that merely 11 days post surgery, the subject'swound has dramatically healed. What is also of note is the level of hairre-growth as can be seen when compared to FIG. 13 a.

At this point it was decided to temporarily stop applying the Vet Creamand allow the wound to heal as it was doing. What was remarkable wasthat little healing took place over the next 10 days. As such, Vet Creamwas reapplied daily for a couple of days which once again promoted notjust rapid healing but further hair growth prior to the subject'sdischarge.

Conclusion

Both veterinarians and the nurse involved had not expected this case toresolve following surgical intervention based on the incredibly foulsepsis at the time of the surgery. Apart from all the other factorsmitigating against recovery, the initial lack of response to antibioticcover and the introduction of a foreign substance in the form of anintramedullary pin into such septic circumstances would normally furtheradd to the difficulty in having any success in clearing up the sepsis.The results obtained were completely unprecedented.

Furthermore, in a large number of cases enhanced tissue regeneration hasbeen seen with hair regrowth. Such enhanced tissue regeneration appearsto extend to septic bone healing in this case. The patient returned tonormal function extremely rapidly demonstrating an analgesic effect, atissue restoration effect covering hair skin, muscle, connective, andbone tissue while at the same time enhancing organ function recovery.

Example 21

A 9 year old female, spayed SharPei/Lab Mix that was hit by a snow plow.She also suffers from epilepsy and SharPei Fever. She was far enough onher driveway that it only severed the lateral 2 digits off her rightfront paw.

The results from the HP Vet Cream (Aconitum Napellus 3×, Arnica Montana3×, Arsenicium lodatum 6×, Belladonna 3×, Bellis Perenis 3×, Bryonia 3×,Calendula Offcinalis 3×, Chamomilla Matricaria 3×, ExchinaceaAngustifolia 3×, Exchinacea Purpurea 3×, Graphites 8×, MamamellisVirginia 3×, Hepar Sulphuris 3×, Hypericum Perforatum 3×, Lachesis 8×,Ledum 3×, Millefolium 3×, Mercurius Solubilis 6×, Phytolacca 6×, RutaGraveolans 3×, Rhus Toxicodendron 3×, Silica 3×, Stellaria Media 3×,Sulfur 3×, Symphytum 3× And Thuja 3×) were very impressive. The ownersstarted with daily sugar bandages for 11 days, then switched to dailyfuracin bandages for 10 days, and HP cream for 14 days.

The results are depicted in FIGS. 14A-14G. FIG. 14A depicts the initialaccident, FIG. 14B depicts the furacin bandages started and Baytril for14 days, FIG. 14C depicts the efucain bandages stopped and the HPhealing cream started, FIG. 14D depicts 6 days after HP cream started,FIG. 14E depicts 14 days after HP healing cream was started, FIG. 14Fdepicts one month after HP healing cream was started and FIG. 14Gdepicts three months after the initial trauma. As indicated in FIG. 14G,the wound is almost completely healed three months after the initialtrauma.

Example 22: Wound Healing Case Studies: Integrating a HomeopathicApproach with Conventional Medicine for Favourable Outcomes

The primary focus of skin lesion management is thorough removal of allforeign material and of all devitalized or contaminated tissue.Effective debridement can reduce but not completely eliminate theconcern about infections. To this end, it is a clinical judgement as tothe need for antibiotic therapy, and if used whether it should beapplied topically, administered systemically or a combination of both.Additionally, sutures and/or bandaging can help provide protection andstructural support that will facilitate wound healing. Nonetheless, evenfor the most skilful veterinarian, some wounds and non-traumatic skinlesions just will not heal.

One aspect of wound healing on which few data are available concerns theuse of homeopathic treatments. Whether as part of routine woundmanagement or in situations of refractory wounds, homeopathic remediescan be a valuable addition to the clinician's armamentarium. To thisend, a homeopathic cream has been developed and tested clinically todetermine its utility in clinical practice. The following examplepresents a number of case studies that suggest that use of the creamfacilitates wound healing in dogs in a range of varied situations.

Case Study 1: Trauma-Induced Foreleg Injury in a Bichon Frise

After being hit by a car, a 7 year-old, male, neutered Bichon Frisesuffered a penetrating wound through the full depth of the dermis of themedial aspect of the left forelimb, extending from the proximalmetacarpus to the axilla. Radiological examination indicated no bonedamage had occurred and there were no additional injuries. Under generalanesthesia, the hair bordering the wound was clipped and the wounddebrided. However, the extent of skin damage, and high risk of woundcontamination and secondary infection precluded suturing. Topicalantibiotic was applied, the wound was bandaged and the patient was senthome on daily oral trimethoprim (5 mg/kg)/sulphadiazine (25 mg/kg), andcarprofen tablets (2 to 4 mg/kg/day).

Three days later, the dog was bright, but there was no evidence ofhealing, and an extensive malodorous, purulent discharge had matted thehair beyond the border of the wound. The owner rejected a second generalanaesthetic, but the dog's docile temperament allowed cleansing of thewound with a water/antiseptic solution and povidone iodine. The dog wassent home with owner instructions to keep the wound as clean as possibleusing saturated salt water. Five days later, the wound had not improvedand the antibiotic was changed to 50 mg clindamycin twice daily, and theowner was instructed to clean the wound with a homeopathic mothertincture calendula (marigold) twice daily (20 drops in 100 ml of sterilewater).

Two weeks after the initial injury (FIG. 15A), healing was not occurringand the wound continued to emit an odour. The dog was again anesthetizedand the wound was clipped, cleaned and bathed in the homeopathic mothertincture calendula and tension sutures were placed, systemic antibiotictherapy was halted and the owner consented to trial a developmentalhomeopathic cream (HP Vet Cream®). After the wound had dried the creamwas liberally applied along with antibiotic ointment. Twenty days afterthe initial injury, and 6 days after the second anaesthetic there wassubstantial improvement (FIG. 15B), and from this point the owner ceasedall other treatment, but continued applying the cream (FIGS. 15C and15D). Approximately one year after the accident, the dog showed completehealing with minimal scarring and almost complete hair regrowth (FIG.15E).

Case Study 2

A 4 year old neutered male Beagle presented with a persistent, circular,purulent wound with necrotic skin on the right pinna (FIG. 16A).Although the etiology was unknown, the owner suspected that the woundoriginated from a spider bite. The dog was administered systemicantibiotic (penicillin injection), and the owner was provided withamoxicillin and HP Vet Cream for application twice daily for one week(FIG. 16B). The dog was re-presented 10 days later for a recheck whenthe wound was significantly reduced in diameter with no sign ofinfection (FIG. 16C). The owner was advised to continue applying thecream and the dog recovered uneventfully.

Case Study 3

A 2-year-old female crossbreed dog was presented with an open wound inthe right inguinal area that penetrated through the superficial musclelayer (FIG. 17A). The wound appeared clean and antibiotics were notconsidered necessary. HP Vet Cream was the only treatment advised, to beapplied to the wound twice daily. FIG. 17 shows the progressiveimprovement in the condition of the wound at 2 weeks and 4 weeks postinitial presentation.

Case Study 4.

A 6 year-old spayed female, mixed breed dog presented with an open woundon the medial aspect of the left stifle. The wound was approximately oneinch in diameter and appeared inflamed and granulomatous (FIG. 18A). Thedog was given an injection of penicillin and the owner dispensed 2 weekssupply of amoxicillin/clavulanic acid tablets. As adjunctive therapy, HPVet Cream was applied, and dispensed for twice-daily application. Atexamination 2 weeks later, the wound was almost completely healed withnew hair growth present and no evidence of infection (FIG. 18B). Theonly treatment advised at this time was to continue twice dailyapplication of the homeopathic cream. Two weeks later, the woundappeared to be completely healed (FIG. 18C).

Case Study 5.

A neutered, 7 year-old male greyhound suffered an extensive full depthskin shearing injury of the dorsum by running under a pole from whichthere was a protruding nut. The extent of affected skin area is shown bythe arrow in FIG. 19A. The wound was debrided and cleaned under generalanaesthesia, including bathing in sterile water with homeopathic mothertincture of calendula (marigold) at a dilution of 20 drops of mothertincture add to 100 ml of sterile water. Mattress sutures were insertedto appose the wound edges, with supporting subcutaenous sutures.Antibiotic cover was instigated with intramuscularamoxicillin/clavulanic acid and maintained with twice daily oraladministration for 5 days. HP Vet Cream was liberally applied to theaffected area and the owner (a veterinary nurse) was instructed to applythe cream to the area at least twice daily. At follow up visits the dogappeared to be recovering well and at a routine visit 12 months afterthe surgery, the wound was seen to have healed well.

In describing four separate cases of trauma induced wounds, this paperdemonstrates the potential for integration of a homeopathic cream intoconventional approaches to managing a range of skin lesions presentedfor veterinary treatment. In the first case, a wound that was refractoryto initial conservative treatment with debridement and antibiotic showedrapid improvement following a change in antibiotic and the applicationof HP Vet Cream. Similarly, a combination of antibiotic with HP VetCream (Case Study 4) produced a good healing response in an infectedstifle wound, and in the most severe wound (Case Study 5), acomprehensive surgical intervention, combined with topical and systemicantibiotic administration and at least twice daily application of HP VetCream produced a full cure.

Not all traumatic wounds described in this paper required supportingantibiotics—in one case of (Case study 3), a deep penetrating woundresponded quickly and thoroughly to application of HP Vet Cream withoutany additional therapy. One case report (Case study 2) described thefavourable response of a wound of unknown origin to combined therapywith the HP vet cream and topical antibiotic.

In case studies such as those described in this paper, it is notpossible to define which of a number of interventions produced a cure,or if it was the exact combination of components together that wasresponsible. However, the positive healing response in which HP VetCream was used alone (Case study 3) does suggest that it offersproperties that can enhance wound healing. Regardless, the casesreported here raise expectations that HP Vet Cream, as either a singleagent or in combination with other topical and systemic therapies suchas antibiotics, has the potential to be a valuable addition to theclinician's armamentarium, whether or not surgery and suturing isutilized.

Example 23: Additional Case Studies

The disclosures of the case studies on http://www.homeopetpro.com arehereby incorporated by reference.

Case #142

4 yr old neutered male Beagle

Patient presented with a “sore” on right pinna. It was suspected thatthe wound was from a possible spider bite. Wound was a circular woundwith necrotic skin and pus exuded. Patient was given an injection ofpenicillin. Wound was clipped and scrubbed with beta dine solution.Patient was sent home with Amoxitabs twice daily for one week. TheHomeopet cream was prescribed for two times per day. Pictures taken areillustrated at FIG. 20A. Patient returned 10 days later for a recheckvisit. Wound was significantly reduced in diameter and infection was notpresent. Owner was advised to continue Homeopet cream. Photo taken isshown at FIG. 20B.

Case #143

1½ yr old spayed DSH feline

Patient presented as non-weight bearing on right front leg. Upon furtherexamination an open, infected, necrotic wound was found. Leg waspreviously swollen per owner before bringing patient in. Wound wasapproximately the size of a nickel. Patient was given a convenia(antibiotic injection) and Homeopet cream prescribed. Photos taken areshown in FIG. 21A. Patient was brought in for a recheck visit after 2weeks. Wound was almost completely healed. Infection was not present andfur was already growing back. Wound was approximately the size of a peaand basically just scabbed over. No further treatment except HomeopetCream was advised. Photos taken are shown in FIG. 21B.

Case #144

2 yr old unneutered Shih Tzu mix

Patient presented after being hit by a car. Oxygen was given and IV cathwas placed. PCV & Total Protein values were obtained. Patient wassedated with Ketamine and Domitor. X-rays were taken. No significantproblems were noted on the x-rays. Abrasions were clipped and cleanedwith beta dyne solution. Patient was given an injection of penicillinand metacam. The abrasions were treated with Homeopet Cream. The patientwas sent home the following day with pain medication (Novox 75 mg) andHomeopet Cream twice daily for the multiple abrasions in the inguinalarea. Owner was advised to bring patient in two weeks for a recheckvisit. Photos taken are shown in FIG. 22.

Case #145

2 yr old female mix breed canine

Patient presented with a wound on the right back side. The wound wasgranulating, non-smelly but open wound in right inguinal. It wassuspected possibly a knife injury—had separation of muscle fibers.Homeopet Cream was the only treatment advised. Patient received HomeopetCream twice daily. Photos taken are shown in FIG. 23A.

Patient returned 2 weeks later for recheck visit. Wound healing well.Photos taken are shown in FIG. 23B. In a recheck visit 2 weeks later,the wound was completely healed at this date. A small scar was present;fur was already trying to come in and cover where wound used to be.Photos taken are shown in FIG. 23C.

Case #146

6 yr old spayed female canine (brown)

Patient presented with an open wound on inside of left rear leg,possibly from a metal shingle. Wound was quarter sized and veryinflamed. The patient was given an injection of penicillin and put onClavamox for 2 weeks. Homeopet Cream was advised and given 2 timesdaily. Photos taken are shown in FIG. 24A.

Patient returned 2 weeks later for a recheck visit. Wound was almostcompletely healed. New hair growth was present. Wound was now dime sizedand healing very well. No infection was present. The only treatmentadvised at this time was to continue the Homeopet Cream. Photos takenare shown in FIG. 24B.

The patient returned 3½ weeks later. The wound was healed and a smallscar present. Photos taken are shown in FIG. 24C.

Case #147

10 yr old female/spayed Collie

Initial Exam: Presented red inflamed, malodorous skin. The patient alsohad difficulty in getting up and down—in obvious pain. A deep pyodermaand a decubitus ulcer were found on the right elbow. There were multiplepapules and pustules all over skin. The patient was in obvious pain asthe ulcer was on a pressure point on the elbow.

The patient was given an injection of penicillin and prednisone. Patientwas sent home with follow up antibiotics and prednisone tablets. TheHomeopet vet cream was advised to be used two times daily. Photos takenare shown in FIG. 25A.

Patient came in for a recheck visit after 3 weeks. The area on rightelbow was slightly improved. Patient was still scratching constantly.New hot spots were forming on the right hip and rump. Patient was givenanother injection of steroid (Depo Medrol) and penicillin. Patient wassent home with 2 more weeks of antibiotics and prednisone tablets.Photos taken are shown in FIG. 25B.

Patient came in for another recheck after 3 more weeks. Foul odor, scabsand sores were still present on skin. The ulcer on right elbow was stillpresent but not as deep. Patient was sent home with more prednisonetablets. A new antibiotic was started on this date (Primor 100 mg).Patient also was given another steroid injection (Dep Med). A secondbottle of Homeopet cream was sent home with the patient. Patient wasadvised to do a recheck visit in 30 days and never returned. Photostaken are shown in FIG. 25C.

Case #148

6 mth old spayed female miniature pinscher

Patient presented with dewclaw incision site open. The patient had anovarian hysterectomy and front dewclaw removal 5 days prior. The dewclawincision site opened presenting open wounds. The wounds were open, redand dime sized. The dewclaw surgery site on both front paws was open butgranulating well. The patient was enrolled in the Homeopet Cream study.The owner was advised to apply the Homeopet cream to both dewclawsurgery sites twice daily. This was the only treatment advised. Photostaken are shown in FIG. 26A.

The patient was brought in 2 weeks later for a recheck. The wounds werealmost completely healed—now pea sized. The fur was almost completelyregrown. The owner was advised to continue Homeopet Cream. Photos takenare shown in FIG. 26B.

The patient returned 3 weeks later for another recheck. Small scars werepresent but wounds were completely healed. Photos taken are shown inFIG. 26C.

Case #149

4 mth old DSH kitten

Patient was presented with a possible woof wound on ventral neck. Woundpresented was open (½ dollar sized) with muscles exposed and odorpresent. The patient was sedated with 25 mg Telazol. The wound wasclipped, scrubbed with Technicare. The patient received an injection ofpenicillin and Metacam. Patient was started on Amoxi Drops twice dailyand Homeopet Cream. The patient's rear right leg was bandaged so thatthe patient would not be able to cause more damage from scratching atwound. Photos taken are shown in FIG. 27A.

Patient returned 2½ weeks later for a recheck visit. The wound wasalmost completely healed with small scar present. Fur was alreadygrowing in and wound was ¼ the original size. No further treatment butHomeopet Cream was advised. Photos taken are shown in FIG. 27B.

Example 24: Human Studies

A 33 year old Male patient with stage 3 renal failure and childhooddiabitices had a non responsive ulcerated would on the left foot isdepicted in FIG. 28A. The wound had been treated with conventional,antibiotics, Hyperbaric chamber, formal surgical wound debridement andwound edge cleaning treatments over a three year period with no success.After just five weeks of once daily treatment with Eycnan LL's Nan'sHealing Cream, (the name of the present invention employed in the humanmarket), the improvement is shown in FIG. 28B. This level of response isboth dramatic and unexpected based on the lack of response to previoustreatments clearly demonstrates that the cream is as effective in humansas it is in animals.

An 53 year old male patient with a chronic non responsive wound that wastreated with conventional antibiotic coverage and Hyberbaric chamber,formal surgical wound debridement and wound edge cleaning treatmentsover a one year period with no success depicted in FIG. 29A. After 3rdweek of cream and compression dressing, the improvement is shown in FIG.29B. The improvement after an additional week is depicted in FIG. 29C.The wound closure in just four weeks is based on once daily applicationof the cream in the wound center.

An 83 year old male patient with a chronic non responsive wound to theright leg was treated with conventional antibiotic coverage andHyberbaric chamber, formal surgical wound debridement and wound edgecleaning treatments over a one year period along with alternating wet tomoist compression bandaging is depicted in FIG. 30A. The next week,cream with compression dressing was added as depicted in FIG. 30B. Theimprovement after the fourth week of treatment is depicted in FIG. 30C.During the 6th week of treatment, compression dressing is no longerneeded as shown in FIG. 30D. The improvement two months after thedepiction in FIG. 30A, is shown in FIG. 30E.

Example 25: HomeoPet Pro HP Healing Cream Case Studies

The cream of the present invention, as exemplified by the presentexample, has proven to be effective on previously non-responsive wounds.The cream creates a protective barrier around a wound and may be used onopen or bandaged wounds. The cream also possesses anti-infectiveactions, has no known negative drug interactions, is anti-inflammatoryand has no known contraindications. The cream is in a safety sealed tubefor ease of application to a wound site.

The healing effect is transferred over the entire wound. As shown inFIG. 31A, septic post surgical mastectomy wound healing with a largearea of slough due to purulent under run of skin tissue which was nonresponsive to the initially selected antibiotic cover in a patient witha febrile state. FIG. 31B demonstrates that the response of this patientto just the use of HP Anti-infective Solution and HP Vet Cream in a casewhich was non responsive to Convenia was to say the least dramatic andprovides an opportunity for the treatment of non-responsive cases in thefuture. Not just did the treatments deal with infection, but theybrought this case from a pretty hopeless state to complete cure in lessthan twenty one days.

The cream has shown, in clinical use, to be effective on previously nonresponsive wounds and ulcerations. As shown in FIG. 32A, wound closureof a chronically infected festering open non healing wound with failureto respond to multiple different antibiotics including topical creams.The dog's owner consented to the use of the dog's case record, so thatother patients could benefit in the way that the dog had. So impressedby the result of the treatment was the dog owner that he not onlyconsented to the use of the initial case records, but he brought the dogback for follow up photographs (see, e.g., FIG. 32B). One of dog owner'smore interesting comments was on how well the dog tolerated the creamsapplication to such a large open and obviously tender wound as theinitial bandaging and un-bandaging had obviously been so painful. Thedog has returned to completely normal activity and unless one knew therehad been a problem no one would know that the dog had ever been injured.

The cream creates a protective barrier around the entire wound. As shownin FIG. 33A, the wound healing of a very extensive degloved injury tothe skin on the back and sides of a greyhound pictured only 24 hoursafter cream application. As shown in FIG. 33B, the patient had anuneventful recovery despite the degree of degloving and the extent ofthe wound and the previous history of the patient's wounds breakingdown. The antibiotic cover was not extended beyond the initial 5 daysand no analgesic or anti-inflammatory other than the HP Vet Cream wasused.

The cream may be used in conjunction with conventional antibiotictherapy to enhance effect. As shown in FIG. 34A, a dog had hair loss,itching and a skin disorder. The owner was administering tripleantibiotic cream twice daily, baking soda baths once a week and dippingin happy jack flea and tick dip. The owner noticed the abrasions beganto turn yellow and looked infected. The owner was subsequentlyinstructed to apply HP Healing cream twice daily for 7-10 days. As shownin FIG. 34B, seven days later, The owner noted that itching had ceased.The skin was much improved and the hair had began to grow back in.

The non-steroidal cream also has non-stringent seals in moisture. FIG.35A depicts incorporation of HP Vet Cream in the treatment of a septiccompound fracture and accompanying wound. FIG. 35B depicts the recoveryin the case, which was dramatic considering the initial prognosis. Whatwas interesting with the use of HP Vet Cream in this case was how itswithdrawal resulted in slower healing until it was reintroduced and alsohow it improved hair growth around the wound

The cream acts as a barricade under which cell regeneration can gounhindered and speed the closure and bridging of wounds. As shown inFIG. 36A, a dog was presented for a laceration on right side. The dogjumped off a fenced in area and caught herself on the fence. The dog wastreated with HP Healing Cream, applied twice daily for 7 days. The dogwas presented 7 days later for a re-check on the laceration on the rightside. Laceration was reduced in size by half, as shown in FIG. 36B. Theowner was instructed to continue to apply HP Healing Cream another twoweeks.

The cream can be used externally on open or bandaged wounds. Liberalapplication is recommended under bandage. FIG. 37A depicts the treatmentof a simple slow healing wound with HP Vet Cream. The patient waspresented to the clinic three weeks after the initial injury with anincised type wound that although small just would not heal and this wasin part the patients own fault as it objected to normal forms of woundclosure. As shown in FIG. 37B, Within two days of starting theapplication of HP Vet Cream the wound had started to heal and the ownerreduced application of the cream to once daily. The wound had healedcompletely within six days of starting application of HP Vet Cream andthe owner ceased applying the cream at that stage with no furtherproblems and this was despite the fact that for the three previous weeksthe wound had steadfastly refused to heal.

The cream works in conjunction with the body's natural healingmechanisms. As shown in FIG. 38A, accelerated wound closure and healingwithout suturing of acute bite wounds compounded with muscle lacerationand severe deep and surface tissue bruising with the use of HP VetCream. As shown in FIG. 38B, the rapidity of healing is very clear whenone looks at the state of the patient where there is a totaldisappearance of tissue bruising and all surface injuries other than themajor wound points had literally vanished. In a patient with noanti-inflammatory or analgesic treatment one would not normally haveexpected the patient to be fully mobile in two days.

An anti-infective and anti-inflammatory effect are naturally provided.As shown in FIG. 39A, accelerated wound closure and healing withoutsuturing of acute bite wounds compounded with muscle laceration andsevere deep and surface tissue bruising with the use of HP Vet Cream. Asshown in FIG. 39B, just 9 days after initial admital, the entire mammaryhypertrophy had disappeared. One can see from the indentations on thepractice golf ball that the cat was back to her initial kitten like selfplaying with toys.

The cream is not listed for use in cases of eczema. As depicted in FIG.40A, there were lesions over the head, has hair loss with crusting andwrinkling of the skin. The cream was possibly being groomed off bykitten. As shown in FIG. 40B, the cat was presented to clinic again oneweek later for no improvement suggesting that the cream may not besuitable for cases of eczema.

This example demonstrates that the cream seals in moisture, ananti-infective, anti-inflammatory effect are naturally provided, ahealing effect is transferred over the entire wound, may be used withconventional antibiotic therapy to enhance effect and is non stringent.The cream acts as barricade under which cell regeneration can gounhindered and speeds the closure and bridging of wounds. The cream canbe used externally on open or bandaged wounds (liberal application isrecommended under bandages). The cream has been shown in clinical use tobe effective on previously non-responsive wounds and ulcerations. Thecream also works in conjunction with the body's natural healingmechanisms.

Example 26: Additional Human Studies

White Female: 60 Years Old

After no response from conventional treatment, including antibiotics andHyperbaric chamber (FIGS. 41A-B), client was placed on the cream (FIGS.41C-D). Improvement was visible after six weeks (FIGS. 41D-E) and twomonths (FIG. 41F). She was able to attend a wedding with open shoes.

Male with Ingrown Hair

A 33 year old male with an ingrown hair that had become a 6 month longtreatment course. The wound was surgically treated to attempt to bringthe wound walls closer to attempt to support healing. Pain medicationalong with conventional antibiotic coverage and Hyberbaric chamber,repeated surgical wound debridement and wound edge cleaning treatmentsover a one year period along with alternating wet to moist compressionbandaging with no success.

In 6 weeks of treatment with the healing cream the wound has progressedto closure and full healing (FIGS. 42A-C). The wound centers doctorswere so impressed with the patients response to the cream that his casewas presented as a poster at a wound healing conference.

The invention is further described by the following numbered paragraphs:

1. An anti-infective homeopathic complex comprising a homeopathictincture or dilutions thereof of Hepar sulphuris calcareum or othersimilar profiled Calcarea or Sulphur salt or acid, Lachesis muta orother remedy with a similar profile, Mercurius Solubilis or similarmercury containing remedy, and Silica or other silica containing remedy.

2. A homeopathic complex according to paragraph 1 wherein HeparSulphuris calcareum is replaced or supplemented with Calc Sulph or CalcSil.

3. A homeopathic complex according to paragraph 1 or paragraph 2 whereinLachesis muta is replaced or supplemented with a snake or spider remedywith a similar septic shock profile, preferably Crotalidae (CrotalusHorridalus), Pyrogen and/or Tarentula Cubensis.

4. A homeopathic complex according to any of paragraph 1 to 3 whereinMercurius Solulbilis is replaced or supplemented with Phytolaccadecandra.

5. A homeopathic complex according to any of the preceding paragraphs ina potency range from mother tincture to 100M, preferably from mothertincture to 50M.

6. A homeopathic complex according to any of paragraphs 1 to 4 in LMpotencies.

7. A homeopathic complex according to any of the preceding paragraphscomprising a homeopathic tincture or dilutions thereof of

the Ranunculacea family, preferably the Aconite or Aconitine, morepreferably Aconite napellus [Acon];

the Compositae family, preferably Arnica montana [Arn]; Bellis perennis[Bell-p]; Calendula Offcinalis [Calen]; Chamomilla Matricaria [Cham];Millefolium achillea [Mill]; Carduus Marianus; and/or Echinacea,preferably Echinacea angustifolia [Echi]; Echinacea purpurea [Echi-p];

the Solanacea family, preferably Belladonna [Bell];

Arsenicum, preferably Arsenicum iodatum [Ars-i] and/or Arsenicum Album;

Bryonia alba [Bry];

Hamamelis virginiana [Ham];

Hypericum Perforatum [Hyper];

Ledum palustre [Led];

Phytolacca decandra [Phyt];

the Anacardiacae family preferably Rhus Toxicodendron [Rhus-T.];

the Rutaceae family preferably Ruta Graveolans [Ruta];

Stellaria media [Stel]; and/or

Symphytum officinale [Symph].

8. A homeopathic complex according to any of the preceding paragraphscomprising a homeopathic tincture or dilutions thereof of

Aconite napellus [Acon]

Arnica montana [Arn];

Arsenicum iodatum [Ars-i];

Belladonna [Bell];

Bellis perennis [Bell-p];

Bryonia alba [Bry];

Calenula Offcinalis [Calen];

Echinacea angustifolia [Echi];

Echinacea purpurea [Echi-p];

Hamamelis virginiana [Ham];

Hypericum Perforatum [Hyper];

Ledum palustre [Led];

Millefolium achillea [Mill];

Phytolacca decandra [Phyt];

Rhus Toxicodendron [Rhus-T.];

Ruta Graveolans [Ruta]; and

Symphytum officinale [Symph].

9. A homeopathic complex according to paragraph 7 or paragraph 8 furthercomprising optional Core B ingredients Thuja Occidentalis [Thuj],Chamomilla Matricaria [Cham], Stellaria media [Stel] and/or Sulphur[Sulph].

10. A homeopathic complex according to any of paragraphs 7 to 9 furthercomprising optional Core B ingredient Graphites naturalis.

11. A homeopathic complex according to any of paragraphs 7 to 10 furthercomprising Apis mellifica [Apis], Urtica urens [Urt-u], and Unbelliferaepreferably Conium maculatum and/or Gunpowder.

12. A homeopathic complex according to any of the preceding paragraphsfurther comprising a homeopathic tincture or dilutions thereof of

The Arsenicums, preferably Arsenicum album [Ars];

The Barytas and Cabonicums, preferably Baryta carbonica [Bar-c] and/orKali Carbonicum;

Carbo vegetabilis [Carb-v];

The Calcareas, preferably Calcarea carbonica [Calc]; Calcarea fluorica[Calc-f] and/or Calcarea phosphorica [Calc-p];

Gelsemium sempervirens [Gels];

Iodium purum [lod];

The Kalis, preferably Kali iodatum [Kali-i] and/or Kali Carbonicum

Lacs, preferably Lac caninum [Lac-c]; Lac vaccinum and/or Lac Vaccinum(cow);

Lycopodium clavatum [Lyc];

The Natrums and Muriatricums, preferably Natrum Mur

Nux vomica [Nux-v];

Phosphorus, preferably Phosphorus [Phos] and/or Ferrum Phos;

the Ranunculacea family, preferably Pulsatilla nigricans [Puls] and/orStaphysagria [Staph];

Sabal serrulata [Sabal];

Sepia succus [Sep]; and/or

Zincums preferably Zincum metallicum [Zinc].

Baptisia tinctoria;

Pyrogen;

Astragalus membranaceus;

Bufo rana; and/or

Ipecacuanha.

13. A homeopathic complex according to paragraph 12 further comprisingCantharis, Causticum, Crategus, Ferrum Phos and/or Laurocerasus.

14. A homeopathic complex according to any of the preceding paragraphsfurther comprising a homeopathic tincture or dilutions thereof of

Adrenalin [Adren];

Aesculus hippocastanum [Aesc];

Alfalfa;

Aurums;

The Antimoniums, preferably Antimonium Tart

Berberis Vulgaris;

Cactus Grandiflora;

Caladium seguinum [Calad];

Cantharis vesicatoria [Canth];

Carduus Marianus;

Cocculus indicus [Cocc];

Chelidonium;

China officinalis;

Chionanthus virginica;

Drosera rotundifolia;

Equisetum hyemale;

Euphrasia:

Galium Aprine;

Grindelia;

Histaminium (Histamine) [Hist];

Hydrastis canadensis [Hydr];

Lappa Articum;

Lavender [Lav-v.];

Lobelia inflata;

Mezereum [Mez];

Nitric acid [Nit-ac];

Paeonia Officinalis [Paeon];

Prednisolone [Predni.];

Ranunculus bulbosus [Ran-b];

Rumex crispus [Rumx];

Solidago virgaurea;

Strophantus hispidus;

Taraxacum officinale;

Triticum Repens;

The Stannums preferably Stannum Met;

Thiosinaminum [Thiosin];

Uva Ursi;

Veratrum Album;

Cuprum met; and/or

Sol [Sol].

15. An anti-infective homeopathic complex comprising a homeopathictincture and dilutions thereof of the following ingredients: HeparSulph; Lachesis; Merc; Sil; Aconite napellus; Arnica montana; Arsenicumiodatum; Belladonna; Bellis perennis; Bryonia alba; Calenula Offcinalis;Chamomilla Matricaria; Echinacea angustifolia; Echinacea purpurea;Graphites naturalis; Hamamelis virginiana; Hypericum Perforatum; Ledumpalustre; Millefolium achillea; Phytolacca decandra; Rhus Toxicodendron;Ruta Graveolans; Stellaria media; Sulphur; Symphytum officinale; andThuja Occidentalis.

16. An anti-infective homeopathic complex comprising a homeopathictincture and dilutions thereof of the following ingredients: AconitumNapellus; Arnica Montana; Arsenicum lod; Belladonna; Bellis Perenis;Bryonia Alba; Calenula Offcinalis; Chamomilla Matricaria; Coniummaculatum; Echinacia augustofolia; Echinacia Purpurea; GraphitesGunpowder; Hamamellis Virginia; Hepar Sulphuris; Hypericum Perforatum;Lachesis; Ledum; Millefolium; Mercurius Solubilis; Phytolacca decandra;Ruta Graveolans; Rhus Toxicodendron; Silica [Sil]; Stellaria Media;Sulphur; Symphytum; Thuja Occidentalis; and Urtica Urens.

17. An anti-infective homeopathic complex according to paragraph 15 orparagraph 16 wherein the homeopathic ingredients are provided in apotency range from Mother tincture to 18×.

18. An anti-infective homeopathic complex according to any of paragraphs15 to 17 in a form suitable for topical administration.

19. An anti-infective homeopathic complex comprising a homeopathictincture and dilutions thereof of the following ingredients: Aconite;Apis; Arnica Montana; Arsencium lod; Belladonna; Bellis Perennis;Bryonia; Calendula; Cantharis; Carbo Veg; Causticum; Conium; Crategus;Echinacea Anugustifolia; Echinacea Purpura; Ferrum Phos; Gelsemium;Hammamellis; Hepar Sulph; Hypericum; Lachesis; Laurocerasus; Ledum; MercSol; Millefolium; Nux Vomica; Phosphorus; Phytolacca; Rhus Tox; RutaGray; Silica; Sulphur; Staphysagria; Symphytum; Urtica; Chamomillamatrica; and Stellaria.

20. An anti-infective homeopathic complex according to paragraph 19wherein the homeopathic ingredients are provided in a potency range from30 C and greater, preferably 200 C and greater and LM potencies.

21. An anti-infective homeopathic complex according paragraph 19 orparagraph 20 in a form suitable for internal administration.

22. A homeopathic complex according to any of the preceding paragraphsfurther comprising nosodes.

23. A homeopathic complex as paragraphed in any of the precedingparagraphs in a form adapted for topical delivery wherein theingredients are present at a potency range from Mother Tincture to 30c,preferably from Mother Tincture to 12c, more preferably from MotherTincture to 9c, even more preferably from mother tincture to 30×.

24. A homeopathic as paragraphed paragraph 23 in the form of a liquid,cream, lotion, gel or in a form adapted for administration in a dressingor bandage.

25. A homeopathic complex as paragraphed in any of the precedingparagraphs in a form adapted for internal delivery wherein the coreingredients are present at a potency range from 1C to 100M, preferably12C to 1M, more preferably from 30 C to 1M, more preferably from 200 Cto 1M, even more preferably 1M to 10M and including LM potencies.

26. A homeopathic as paragraphed paragraph 25 in the form of an oraltablet, pill, pillule, gel cap, spray and/or drop.

27. A homeopathic complex as paragraphed in any of the precedingparagraphs further comprising conventional pharmaceutical excipientsand/or carriers.

28. A combination therapy comprising the homeopathic complex asparagraphed in any of the preceding paragraphs and a conventionalpharmaceutical.

29. A combination therapy according to paragraph 28 wherein theconventional pharmaceutical is an orally administered antibiotic ortopically administered antibiotic.

30. A homeopathic complex as paragraphed in any of the precedingparagraphs for use in therapy.

31. A homeopathic complex as paragraphed in any of the precedingparagraphs for use in the treatment or prophylaxis of infection as ananti-infective agent, preferably in the treatment, control orprophylaxis of MRSA or other multi-resistant microbial strains.

32. A homeopathic complex as paragraphed in any of the precedingparagraphs for use in the regeneration of diseased or damaged tissue.

33. A homeopathic complex as paragraphed in paragraph 16 for use in thetreatment of mastitis.

34. A homeopathic complex as paragraphed in paragraph 19 for use as afirst aid remedy.

35. A homeopathic complex as paragraphed in any of the precedingparagraphs for use in the treatment of humans and animals, includingcanines, equines, porcine and/or felines.

36. A method for the manufacture of a medicament comprising ahomeopathic complex as paragraphed in any of paragraphs 1 to 27 for usein the treatment or prophylaxis of infection and/or the regeneration ofdiseased or damaged tissue.

37. A method for the treatment or prophylaxis of infection and/or theregeneration of diseased or damaged tissue in a subject comprising thesteps of administering an effective amount of a homeopathic complex asparagraphed in any of paragraphs 1 to 27 to a patient in need of suchtreatment.

38. A cosmetic preparation comprising a homeopathic complex asparagraphed in any of paragraphs 1 to 27 and a suitable cosmeticcarrier.

Having thus described in detail preferred embodiments of the presentinvention, it is to be understood that the invention defined by theabove paragraphs is not to be limited to particular details set forth inthe above description as many apparent variations thereof are possiblewithout departing from the spirit or scope of the present invention.

What is claimed is:
 1. A method for treating a wound caused by radiationtherapy in a subject in need thereof, which comprises administering aneffective amount of a topical composition comprising Hepar Sulphuriscalcareum, Lachesis muta, Mercurius Solubilis, and silica to said woundcaused by radiation therapy.
 2. The method according to claim 1, whereinthe composition further comprises Aconite napellus, Amica montana,Arsenicum iodatum, Belladonna, Bellis perennis, Bryonia alba, CalendulaOfficinalis, Echinacea angustifolia, Echinacea purpurea, Hamamelisvirginiana, Hypericum Perforatum, Ledum palustre, Achillea millefolium,Phytolacca decandra Rhus Toxicodendron, Ruta Graveolans, and Symphytumofficinale.
 3. The method according to claim 1, wherein the compositionfurther comprises Chamomilla Matricaria, Graphites naturalis, Stellariamedia Sulfur, or Thuja Occidentalis.